

Curriculum Vitae

Quyên D. Chu, M.D., M.B.A., F.A.C.S.

Professor of Surgery, tenured
Roy L. Schneider Endowed Professor of Surgery
Chief, Surgical Oncology
Associate Director of Cancer Center
Howard University School of Medicine
Washington, DC

PERSONAL:

Office Address: Howard University Hospital
2041 Georgia Avenue
Washington, DC 20060

Email Address: quyen.chu@howard.edu
qdchu2010@gmail.com

Telephone: (318) 655-1358 (Cell)

Home Address: 2014 van Buren Street
Hyattsville, MD 20782

Citizenship: United States

AREAS OF EXPERTISE:

CLINICAL Hepato-pancreato-biliary (HPB) cancers
Esophageal Cancer
Breast Cancer
Gastric Cancer
Advanced/Recurrent Solid Tumors
Sarcomas
Colorectal cancers
Melanomas
The cytoreductive surgery and hyperthermic intraperitoneal
chemoperfusion program (HIPEC)

RESEARCH Oncolytic viruses
Chemokine receptor CXCR4
Breast and Pancreatic Cancer

BUSINESS

Founded Beaux Books Publishing Company

DIRECT PATIENT CARE

August 2002- January 2021
LSU Health Sciences Center-Shreveport
Shreveport, Louisiana
Colleague: Gazi Zibari, MD
318-820-4667

January 2021- November 2023
Orlando Health
Orlando, Florida
Partner: Raj Nair, MD
321-229-0619

November 7, 2023- current
Howard University
Washington, DC
Chair: Terrence Fullum, MD

EDUCATION:

06/1990	B.A.	Dartmouth College Biochemistry, Hanover, NH
06/1994	M.D.	Brown Medical School Providence, RI
06/2013	M.B.A.	Executive MBA Frost School of Business Centenary College, LA

POSTGRADUATE TRAINING:**Internship and Residency:**

09/1995 – 06/1997	Internship in General Surgery, Baystate Medical Center, Springfield, MA
06/1997 – 08/1999	Residency in General Surgery, St. Elizabeth's Medical Center, Boston, MA
08/1999 – 06/2000	Chief Resident, General Surgery,

St. Elizabeth's Medical Center, Boston, MA

Research Fellowships:

06/1994 – 06/1995

Research Fellow
Department of Surgery
Brown University School of Medicine, Providence, RI
Mentor: Harold J. Wanebo, M.D.

Clinical Fellowship:

09/2000 – 06/2002

Surgical Oncology,
Roswell Park Cancer Institute, Buffalo, NY

Postgraduate Courses:

2003

Clinical Trials Methods: American College of Surgeons

2004

Young Surgical Investigators Conference:
Leesburg, VA

2008

Mammosite course
San Antonio, TX

2008

Disparities in Surgical Care: Research to Practice
Boston, MA

2009

2nd Annual Meeting of the Global Burden of Surgical
Disease Working Group
Chicago, IL

2009

ASCO 2009-2010 Leadership Development Program
Virginia, VA

2009

American College of Surgeons Leadership Conference
Washington DC

2010

Laparoscopic Esophagectomy
Gainesville, FL

2010

American College of Surgeons Leadership Conference
Washington DC

2011

Fierce Conversation Leadership Course
Washington D.C.

2012

American College of Surgeons Leadership Conference
Washington DC

LICENSURE:

1995 State of Massachusetts (Inactive) No. 158025 (inactive)
2000 State of New York (Inactive) No. 216929-1 (inactive)
2002 State of Louisiana No. 14685R (inactive)
2022 State of Florida ME 154104(active)
2023 Washington, DC MD210012342 (active)
2023 State of Virginia 0101280322 (active)
2023 State of Maryland D0098854 (active)

BOARD CERTIFICATION:

2001 American Board of Surgery No. 046594
Candidate ID# 057968
Initial Certification: 10/29/2001
Recertification 12/09/2009
Recertification 09/24/2022

2002 Surgical Oncology and Endoscopy Certificate: Society of
Surgical Oncology

SPECIAL CERTIFICATION

1995 Surgical Oncology Basic Science Certification:
Brown University School of Medicine

1998 Advanced Laparoscopic Solid Organ Surgery:
Splenectomy and Adrenalectomy: Providence, RI

1998 Trauma Abdominal Ultrasound: Bridgeport Hospital
Section of Trauma and Surgical Critical Care at USSC,
Norwalk, Conn

2003 Endorectal Ultrasound. The American Society of Colon
and Rectal Surgeons, New Orleans, LA

2003 ATLS re-certification

NATIONAL APPOINTMENT:

2013-2015	Presidential Appointees to the Vietnam Education Foundation (VEF) Board (President Barack Obama)
2020	Advisory Board for Medical Engineering Innovations, Inc

ACADEMIC APPOINTMENTS:

2002 - 2007	Assistant Professor of Surgery, Louisiana State University, Shreveport, LA
2007 – 2012	Associate Professor of Surgery (tenured) Louisiana State University, Shreveport, LA
2012- 2022	Professor of Surgery (tenured) Louisiana State University, Shreveport, LA
2022- present	Professor of Surgery University of Central Florida Orlando, FL
2023-present	Professor of Surgery Howard University Washington, DC

HOSPITAL APPOINTMENTS:

2002 - 2022	Surgical Oncologist, Division of Surgical Oncology, Louisiana State Univ. Health Sciences Center, Shreveport, LA
2003 - 2004	Consultant Surgeon, Overton-Brooks V.A. Medical Center, Shreveport, LA
2003 – 2022	Consultant Surgeon, Willis-Knighton Medical Center, Shreveport, LA

2004 - 2022	Consultant Surgeon, Doctor's Hospital Shreveport, LA
2005-2022	Director, Peritoneal Surface Malignancies Program Louisiana State Univ. Health Sciences Center, Shreveport, LA
2008-2022	Chief of Surgical Oncology Louisiana State Univ. Health Sciences Center, Shreveport, LA
2009-2013	American College of Surgeons Commission on Cancer (CoC) Cancer Liaison
2015-2018	Vice-Chair of Academic Affairs
2015-2022	Director of Hepato-Pancreato-Biliary Services
2019-2022	Promotion and Tenure Committee

MAJOR COMMITTEE ASSIGNMENTS:

International Organization:

2010 – 2012	National Foundation for Science and Technology Development (NAFOSTED) (Vietnam's NSF) Biology Leader for Reviewers
2013-current	World Health Organization Global Initiative for Emergency and Essential Surgical Care (WHO-GIEESC)

National Organizations:

2003 - 2022	Principal Investigator and Group Leader American College of Surgeon Oncology Group
2004 - 2022	Southwest Oncology Group (S.W.O.G.)
2005- 2022	Association of Academic Surgery Institutional Representative
2008 - 2022	SWOG Breast Cancer Committee

	SWOG Gastrointestinal Cancer Committee
	SWOG Surgery Committee
2009-2012	American College of Surgeons Young Fellows Association Governing Councilor
2010-2012	2010 Nominating Committee Young Fellows Association
2010-2012	2010 International Relations Committee Young Fellows Association
2010-2012	American College of Surgeons Board of Governors: Liaison for International Relations Committee
2010-2011	American Society of Clinical Oncology (ASCO) Program Director: Oncology Training Program in Vietnam
2010-2011	American Society of Clinical Oncology (ASCO) Cancer Education Committee-Member
2010-2011	American Society of Clinical Oncology (ASCO) International Cancer Corps (ICC) Member
2010-2011	American Society of Clinical Oncology (ASCO) Cancer Genetics Curriculum Committee
2010-2011	Health Volunteers Overseas (HVO) Oncology Steering Committee
2011 – 2013	AAS: Publication Committee
2011- 2012	SUS: Publication Committee
2001-2019	American Society of Breast Surgeons
2011- 2012	Department of Defense Congressionally-Directed Medical Research Programs (CDMRP): Detection Diagnosis and Prognosis Scientist Reviewer
2011- 2012	Chair Surgical Oncology Committee for International College of Surgeons
2011- 2012	ASCO Physician Wellness Steering Committee

2011- 2012	ASCO Leadership Development Program Working Group
2011- 2012	American College of Surgeons: International Scholar Selection Subcommittee
2012-2013	AAS Subcommittee Best Overall Manuscript
2012-2014	American College of Surgeons Governors Committee on Chapter Activities YFA Liaison
2012-2013	VEF: Selection Committee for U.S. Faculty Scholar
2012	ASCO International Development and Education Program (IDEA) Guest: Cooper Hoover, M.D., Honduras
2012-2014	ASCO Tumor Boards Planning Committee
2012-2014	AHPBA Institutional Membership Liaison
2012-2014	AHPBA Program Committee
2012-2014	ASCO IMT Committee Ed Book Editor Search Task Force
2013-2014	American College of Surgeons-Emerson Scholar-in-Residence committee member
2013-2014	International College of Surgeons: Vice-President
2013-2015	ASCO University Associate Editor
2013-2015	Finance Committee of AHPBA
2013	ASCO International Development and Education Program (IDEA) Guest: Micheal Misauno, M.D., Nigeria
2013	American College of Surgeons Community Surgeons Travel Award Mentor (Dr. Adesoji Ademuyiwa from Nigeria)
2013-2014	Department of Defense Congressionally-Directed Medical Research Programs (CDMRP): Detection Diagnosis and Prognosis Scientist Reviewer
2013-2014	Chair of Education, Quality and Communications Subcommittee of International Relations Committee of the ACS

2013-2015	Nominating Committee of the International Relations Committee of the ACS
2013-2015	Executive Committee of the International Relations Committee of the ACS
2012-2014	ACS Scholarship & Philanthropy Subcommittee Goals
2013-2014	Selection Review Committee for the VEF
2013-2015	CoC State Chair
2014-2016	SESAP 16 Committee
2014-current	CoC Committee
2015-2016	ASCO Writing Committee
2015-2017	Publication Committee: Americas Hepato-Pancreato-Biliary Association (AHPBA)
2015-2017	Selection Committee for the American College of Surgeons Brandeis General Surgery Health Policy Scholars
2016	Co-Chair of AHPBA Publications Committee
2016	Program Committee of the American College of Surgeons-Liaison
2016	Secretary of the Louisiana Chapter of the ACS
2017	AACR Breast Cancer Research Grants Scientific Review Committee
	Selection Committee for the Americas Hepatopancreato-Biliary Association (AHPBA) Brandeis Health Policy Scholars
	SUS Membership Committee Member
	SESAP 17 Committee
	AHPBA Executive Council: Members at Large
	ASCO Special Awards Selection Committee

2018-2019	ACS/American Society for Breast Surgeons (ASBrS) International Scholarship Reviewer
2019	<p>Chair of AHPBA Publications Committee</p> <p>CoC State Chair Outstanding Achievement Award Committee</p> <p>Vice-Chair of Cancer Liaison Physician Committee of CoC</p> <p>CoC Mentor</p> <p>Surgery: Editorial Board Member</p>
2020	<p>Selection Committee for ACS/American Society of Breast Surgeons (ASBrS) International Scholarship</p> <p>Created the Louisiana Cancer Consortium</p> <p>CoC Paper Competition Advisory Group</p>
2021	<p>IHPBA Publications Committee</p> <p>Commission on Cancer Rural Hospital Task Force\</p> <p>CoC Nominating Committee</p>
2021-2022	<p>ACS Board of Governors</p> <p>ACS Board of Governors Survey Workgroup</p>
2022	<p>ASCO Leadership Development Program Selection Committee</p> <p>ASCO SEP Writing Task Force</p>
2023	<p>ASCO LDP - Team Mentor/Coach</p>

State/Regional Organizations:

2004-2005	<p>Delegate for 2004 House of Delegates of the Louisiana State Medical Society</p>
2003-2004	<p>Young Surgeon Representative, LA Chapter, American College of Surgeons</p>
2002 - 2003	<p>Committee member, Cancer Early Detection and Prevention Group Louisiana Cancer Control Partnership</p>
2008- 2009	<p>Committee member, Louisiana HealthCare Quality Forum-</p>

	Quality Measurement Committee
2009-2010	Executive Councilor Surgical Association of Louisiana
2010- 2012	Chair, Resident Surgical Jeopardy Joint Annual Meeting Louisiana Chapter, American College of Surgeons and Surgical Association of Louisiana
2009-	State Advocacy Representative
2011-	John C. McDonald Surgical Society Treasurer
2012	9 th Annual Vietnam Education Foundation Conference Chair, Program Committee
2013	John C. McDonald Surgical Society President
2014	Surgical Association of Louisiana (SAL) Vice-President
2015	Surgical Association of Louisiana (SAL) President
2015	Treasurer Louisiana Chapter-American College of Surgeons
2016	Louisiana Department of Health and Human Services- Healthy Louisiana Adult Medicine Subcommittee Member
2016	Secretary Louisiana Chapter-American College of Surgeons
2017	Vice-President Louisiana Chapter-American College of Surgeons
2019	President-Elect Louisiana Chapter-American College of Surgeons CoC State Chair Advisory Board
2020	President-Louisiana Chapter-American College of Surgeons

Hospital Committees:

2003 – 2005	Trauma Performance Improvement Committee
2003- 2020	Resident Promotion Committee
2004 – 2005	Clinical Research Committee
2004 – 2005	Surgery Quality Council Committee
2007-2008	Infection Control Committee
2007- 2008	Medical Student Research Committee
2007- 2008	Medical Student Promotion Committee
2007- 2008	Breast Cancer Focus Group
2009-2011	Surgical Care Improvement Project (SCIP) Chairperson
2009- 2011	Continuing Medical Education Committee Faculty Advisory Committee
2009-2022	Hepatopancreatico-Biliary Multidisciplinary Team Core Member
2010- 2011	Residency Service Committee: Ad-Hoc Chairperson
2010- 2011	2010 Joint Commission Process Review Committee
2011- 2014	Institutional Review Board Member
2011- 2012	Search Committee for Department of Otolaryngology Committee Member
2011 – 2014	Feist Weiller Cancer Center Research Advisory Committee
2011 – 2012	Operative and Other Invasive and Noninvasive Procedures Committee
2012-2019	Department of Surgery Policy Committee
2013-2022	Department of Surgery Promotion & Tenure Committee
2016-2018	Bylaws Committee

2019-2022 Institutional Promotion and Tenure Committee

NON-ACADEMIC ACTIVITIES

2004 – 2008 Dartmouth College District Enrollment Director
for North Louisiana

2004 – 2022 Brown University interviewer for North Louisiana

2011 - 2012 World Surgical Foundation, Louisiana Chapter, Incorporated
501 (c) 3 non-profit organization
Founder and Vice-President

2015-present Beaux Books Publishing-Executive Director

2014-2015 Political Campaign Manager to Elect A Candidate for District
Court Judge

2017-2019 Dartmouth College Gift Planning Chair
Class Officer for Class of 1990

PROFESSIONAL SOCIETIES:

National Organizations:

2002 American Association for Cancer Research*

2002 Association for Academic Surgery*

2003 Southwest Oncology Group*

2002 Roswell Park Surgical Society

2002 American Society for Gastrointestinal Endoscopy*

2002 American Society of Clinical Oncology*

2000 Society of Surgical Oncology *

1999 American College of Surgeons*

2003 American Society of Breast Surgeons *

2003 American College of Surgeons Oncology Group *

2005 American Hepato-Pancreato-Biliary Association *

International Hepato-Pancreato-Biliary Association*

American Society of Gene Therapy*

2009 American Society of Peritoneal Surface Malignancies
2010 Society of University Surgeons*
2010 Surgical Political Advocacy Committee (SPAC)
2011 Southern Surgical Association*

(*elected membership)

State Organizations:

2003 Louisiana Chapter, American College of Surgeons
2003 Louisiana State Medical Society
2003 Shreveport Medical Society*
2003 Shreveport Surgical Society*
2003 Surgical Association of Louisiana*

(*elected membership)

HONOR SOCIETIES:

1993 Sigma Xi Honor Society

AWARDS/HONORS:

1990 Dartmouth Scholars Award
1990 - 1994 Brown Faculty Scholars Award
American Federation of Clinical Research (AFCR) Award
Norton Cancer Institute Research Fellowship Award
Mt. Sinai Medical Student CPC Competition Award
2000 – 2002 Research Grant Award, Division of Head and Neck Surgery
Roswell Park Cancer Institute, Buffalo, NY
Travel Grant to CALG-B meeting, Ottawa, ON

	Travel Grant to CALG-B meeting, Amelia Island, FL
2004	Young Surgeon Representative, Louisiana Chapter, American College of Surgeons Delegate to the Louisiana State Medical Society
2005	Brown University / Bank of America Community Fellows Awards Health Resources and Services Administration (HRSA) Faculty Loan Repayment Program Award Team Recognition Award Louisiana State Univ. Health Sciences Center, Shreveport, LA
2007	2007 ASCO Foundation Merit Award Role: Mentor
2008	Shreveport-Bossier Best Doctor
2009	1. Albert Sklar Endowed Professorship 2. ASCO 2009-2010 Leadership Development Program 3. U.S. Faculty Scholar Award from Vietnam Education Foundation 4. Shreveport-Bossier Best Doctor 5. USA Today “Most Influential Doctors”
2010	1. VFW Ladies Auxillary Cancer Award 2. U.S. Faculty Scholar Award from Vietnam Education Foundation 3. International Teaching Award from Thai-Binh Medical University, Vietnam 4. Shreveport-Bossier Best Doctor 5. USA Today “Most Influential Doctors”
2011	1. Charles D. Knight, Sr. Endowed Professor in Surgery
2012	1. Vietnam Education Foundation (VEF) Exceptional Service Award 2. 2012/2013 ACS Japan Traveling Fellow Award
2013	1. Presidential Appointee to the Board of the Vietnam Education

- Foundation (National)
 - 2. U.S. News/Castle Connolly Top Doctors (National)
 - 3. Most Outstanding VEF Alumni Award (National)
 - 4. Team Recognition Award (Local)
 - 5. Evening for Heroes Award (Local)
 - 6. Vitals Top 10 Doctors (National)
 - 7. Vietnamese Culture & Science Association Special Contribution Award (National)
- 2014
- 1. National Ethnic Coalition of Organizations (NECO)/ Ellis Island Medals of Honor
 - 2. Best Oral Award for the 2014 IHPBA World Congress
 - 3. SB Magazine-Best Doctor
 - 4. U.S. News/Castle Connolly Top Doctors (National)
- 2015
- 1. American College of Surgeons: Scholarship for the Brandeis Leadership Program in Health Policy and Management
 - 2. 2015 AHPBA North and South American Annual Traveling Fellowship
- 2016
- 1. ASCO Humanitarian Award
 - 2. American Registry 2016 America's Most Honored Professionals Award
 - 3. Castle Connolly Top Doctors (National)
 - 4. Business of Excellence Innovative Technology Award: Southern Hospitality Exposure Magazine
 - 5. Marshal Convocation for American College of Surgeons
- 2017
- 1. AHPBA Humanitarian Award
 - 2. Best Teaching Faculty Award
 - 3. Castle Connolly Top Doctors (National)
 - 4. Marqui's Who's Who
- 2018
- 1. Presidential Leadership Scholars Award
 - 2. U.S. News/Castle Connolly Top Doctors (National)
 - 3. Edward & Freda Green Professorship in Surgical Oncology
- 2019
- 1. U.S. News/Castle Connolly Top Doctors (National)
- 2020
- 1. CoC State Chair Outstanding Performance Award
 - 2. LA-ACS Charles Lester Black Humanitarian Award
 - 3. U.S. News/Castle Connolly Top Doctors (National)
 - 4. Louisiana Top Doctors (Louisiana Life, November issue)
- 2021
- 1. U.S. News/Castle Connolly Top Doctors (National)
 - 2. Best CoC Paper: Louisiana Chapter of ACS Annual Meeting

2022 1. Best CoC Paper: Florida Chapter of ACS Annual Meeting

INITIATED PROJECTS

2009 Program Director
16th Annual Carroll W. Feist Scientific Symposium on
Hepatocellular Carcinoma

2009 July 17, 2009
Program Director
1st Annual Hepatopacreatobiliary Conference
November 20, 2009

2010 July 23, 2010
Program Director
17th Annual Carroll W. Feist Scientific Symposium on
Esophageal Carcinoma

2010 October 3-13, 2010
First International Vietnam-American Surgical Symposium
Hanoi, Vietnam
Program Director

2010 Coordinator of Surgical Grand Rounds
Biology of Colorectal Neoplasia
Thomas J. McGarrity, M.D.
April 6, 2010

2011 Coordinator for 97th Annual Clinical Congress of American
College of Surgeons, “Volunteering: Making Service Happen”.
San Francisco, CA , October 23-27, 2011.

2011 April 15-25
First Annual Joint ICS/Operation Hope and AHPBA Medical
Symposium, Kurdistan, Iraq
Program Director

2011 Host & Coordinator for 2012 Vietnam Education
Foundation (VEF) Annual Conference
Shreveport, LA

2013 Committee Organizer for
AHPBA 3rd Workshop in Managua, Nicaragua

- 2014 Program Director for 5th Annual Joint Americas Hepato Pancreato-Biliary Association, Operation Hope, World Surgical Foundation & the American Kurdish Medical Group Symposium Duhok-Kurdistan, Iraq, May 23, 2014
- 2015 Program Director for 6th Annual Joint Americas Hepato Pancreato-Biliary Association, Operation Hope, World Surgical Foundation & the American Kurdish Medical Group Symposium Duhok-Kurdistan, Iraq, April 9, 2015
- 2017 Program Director for 8th Annual Joint Americas Hepato Pancreato-Biliary Association, Operation Hope, World Surgical Foundation & the American Kurdish Medical Group Symposium Duhok-Kurdistan, Iraq, May 25, 2017
- 2018 Program Director for 9th Annual Joint Americas Hepato Pancreato-Biliary Association, Operation Hope, World Surgical Foundation & the American Kurdish Medical Group Symposium Duhok-Kurdistan, Iraq, August 30, 2018

TEACHING EXPERIENCE:

- 2000-2002 Lecturer, Roswell Park Cancer Institute Fellow's Lecture Series
1 lecture per year
- 2002 -2022 Clinical Preceptor, Lecturer and Attending Surgeon,
Surgical Oncology Service, LSU Health Sciences Center,
Shreveport, LA
- 2003 - 2022 Co-Coordinator, Multidisciplinary Tumor Board,
LSU Health Sciences Center
Weekly meeting
- 2003 – 2022 Co- Coordinator, Surgical Oncology Journal Club,
LSU Health Sciences Center
Weekly meeting
- 2003 – 2018 Surgical Oncology Laboratory Meeting,
LSU Health Sciences Center
Weekly meeting
- 2002 - 2022 Faculty, Surgery Grand Rounds,
LSU Health Sciences Center

2 lectures per year

2003 - 2022 Faculty, Oral Examinations to Residents
LSU Medical School – Shreveport
4 Examinations per year

2003-2020 Faculty, 3rd year Medical Students Lecture
LSU Health Sciences Center
3 lectures per year

2003 Surgery Grand Rounds
Pancreatic Cancer

2003 Faculty speaker, 5th Annual Red River Gastrointestinal Conference
Shreveport, LA

2004 Surgery Grand Rounds
Gastric Cancer

2004 Surgery Grand Rounds
Retroperitoneal Sarcoma

2004 Surgery Grand Rounds
Surgical Oncology Research Program

2004 Surgery Grand Rounds
Hematologic Indications for Splenectomy

2005 Phoenix Multidisciplinary Cancer Symposium
Gastrointestinal Carcinoid Tumors

2005 Surgery Grand Rounds
Prophylactic Surgery for Inherited Cancer Syndrome

2006 Surgery Grand Rounds
Adjuvant Therapy for Node Positive Breast Cancer

2006 Head and Neck Grand Rounds
Current Management of Esophageal Cancer

2006 Asian/Pacific Islander Diversity Awareness Talk
National Weather Service

2007 LCPPC: Current Perspectives on Management of Colorectal Cancer

2007 Surgery Grand Rounds

Translational Breast Cancer Research

- 2007 How to Perform a Proper Breast Examination
Lecture to Second Year Medical Student
- 2007 Surgical Faculty Mentor for 1st year Medical Students
- 2008 Hepato-Pancreato-Biliary Disorders
Lecture to Physician Assistant Students
- 2008 How to Perform a Proper Breast Examination
Lecture to Second Year Medical Student
- 2008 Surgical Faculty Mentor for 1st year Medical Students
- 2009 Hepato-Pancreato-Biliary Disorders
Lecture to Physician Assistant Students
- 2009 Melanoma
Grand Rounds
- 2009 How to Perform a Proper Breast Examination
Lecture to Second Year Medical Student
- 2009 Surgical Faculty Mentor for 1st year Medical Students
- 2010 Hepato-Pancreato-Biliary Disorders
Lecture to Physician Assistant Students
- 2010 How to Perform a Proper Breast Examination
Lecture to Second Year Medical Student
- 2010 Surgical Faculty Mentor for 1st year Medical Students
- 2011 Melanoma
Grand Rounds
- 2011 Sarcoma
Grand Rounds
- 2018 Esophageal Cancer
ENT Grand Rounds
- 2020 Esophageal Cancer
ENT Grand Rounds

LABORATORY/RESEARCH MENTORSHIPS:

	<u>Years in Lab</u>	<u>Present Position</u>
Undergraduates/High School:		
Melissa Macynski	2003	Louisiana College Pineville, LA
Joshua Lee Jordan	2003	C. E. Byrd High School Shreveport, LA
Marco Reyes	2004	Bossier High School Bossier City, LA
Chiemeka Izundu	2004	Woodlawn High School Shreveport, LA
Takazvida A. Nyaundi	2004	Wiley College Marshall, TX
Lisa Sun	2005	Magnet High Shreveport, LA
Rani Veda	2006	University of Louisiana, Monroe Shreveport, LA
Robert Grand	2006-2011	Caddo Magnet High Shreveport, LA
Matthew Pope	2009-2011	Ouachita Baptist University Arkadelphia, Arkansas
Medical Students		
Julie Guidroz	2005	LSU-Shreveport Shreveport, LA
John Navas	2005	LSU-Shreveport Shreveport, LA

Taylor Robertson	2007	LSU-Shreveport Shreveport, LA
Anthony Flowers	2008	LSU-Shreveport Shreveport, LA
David Hiller	2008-10	LSU-Shreveport Shreveport, LA
Krista Pennington	2008-10	LSU-Shreveport Shreveport, LA
Hannah Bauer	2010	LSU-Shreveport Shreveport, LA
Justin Rudd	2010	LSU-Shreveport Shreveport, LA
Ashley Arnold	2010	LSU-Shreveport Shreveport, LA

Postgraduate Fellows/Residents:

Stephen White, M.D.	2003 - present	General Surgery Resident, LSU Health Sciences Center Shreveport, LA
Derek McClusky, M.D.	2003 - present	General Surgery Resident, LSU Health Sciences Center Shreveport, LA
Kerry Byrnes, M.D.	2003 - present	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Mohamed Alassas, M.D.	2003 - present	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Ryan Wolfort, M.D.	2004	General Surgery Resident LSU Health Sciences Center Shreveport, LA

M. Scott Connor, M.D.	2004	Oral Maxillofacial Surgery Resident LSU Health Sciences Center Shreveport, LA
Salvador Vazquez, M.D.	2004	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Eric Amy, M.D.	2004	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Neil Holm, M.D.	2006	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Mark Smith, M.D.	2008-11	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Catherine Parker, M.D.	2009-11	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Amanda Henderson, M.D.	2009-11	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Joseph Zakhary, M.D.	2009-11	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Alireza Jahromi, M.D.	2010-2011	Research Fellow LSU Health Sciences Center
Beth Townsend, M.D.	2012-2014	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Catherine Parker, M.D.	2012-2013	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Arielle Dubose, M.D.	2012-2014	General Surgery Resident LSU Health Sciences Center

		Shreveport, LA
Alireza Jahromi, M.D.	2013-17	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Beth Townsend, M.D.	2014-2015	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Kaelen Medeiros	2015	Biostatistician Graduate Student LSU-New Orleans New Orleans, LA
Meijiao Zhou	2015	Biostatistician Graduate Student LSU-New Orleans New Orleans, LA
Conner McDaniel	2017	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Rachel Shirley	2017	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Lloyd Jones	2017	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Patton Pennington	2017	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Yoko Sang	2017	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Adebayo Awe	2017	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Justin Rudd	2017	General Surgery Resident LSU Health Sciences Center Shreveport, LA

Clint Schoolfield	2017	General Surgery Resident LSU Health Sciences Center Shreveport, LA
Karnika Singh	2017	Ph.D Candidate Clinical Translational Distinction Tract LSU Health Sciences Center Shreveport, LA

Faculty

Roger Kim	2009-current	Surgical Oncology Tenured Associate Professor LSUHSC-Shreveport
Mallory Williams	2009-current	Trauma/Surgical Critical Care Chief, Trauma Tenured Associate Professor Howard University
Sreyram Kuy	2012-current	Chief Medical Officer Medicaid, Louisiana Department of Health Deputy Under Secretary for Community Care-US Department of Veterans Affairs
Navdeep Samra	2012-current	Trauma/Surgical Critical Care Tenured, Associate Professor LSUHSC-Shreveport
Tan Tze-Woei	2012-current	Vascular Surgery Assistant Professor University of Arizona
Prakash Peddi	2015-current	Assistant Professor of Medicine LSUHSC-Shreveport
Shuja Ahmed	2016-current	Assistant Professor of Medicine LSUHSC-Shreveport
Anand Annamalai	2016-current	Assistant Professor of Surgery Cedar Sinai-California

International Physicians:

Hoover Cooper, M.D.	2012	Surgical Oncologist
---------------------	------	---------------------

		Hospital General San Felipe Honduras
Michael Misauno, M.D.	2013	Surgical Oncologist Jos University Teaching Hospital Nigeria
Florence Dedey	2017	Surgical Oncologist Ghana
Sana Badar	2017	Fellow Willis-Knighton Medical Center Shreveport, LA

AWARDS AND HONORS WON BY RESIDENTS/STUDENTS:

Wolfort, Ryan, M.D.	2005	State Cancer Paper Competition Winner American College of Surgeons, LA-Chapter
Byrnes, Kerry, M.D.	2005	2 nd place State Cancer Poster Competition American College of Surgeons, LA-Chapter Winner of the 2005 Jim Cardelli Barlow Symposium Award
Salvador Vazques, M.D.	2006	State Cancer Paper Competition Winner American College of Surgeons, LA-Chapter
Lisa Sun, B.A.	2006	First Place Winner of State-Wide Medicine and Health Research Competition
Neal Holm, M.D.	2007	2007 ASCO Foundation Merit Award
Neal Holm, M.D.	2007	American Cancer Society/ LA. Cancer Competition Award
Neal Holm, M.D.	2008	American Cancer Society/LA. Cancer Competition Award
David Hiller	2009	Finalist in the AAS Outstanding Medical Student Presentation
Neal Holm, M.D.	2010	Best Resident Presentation Award-Department of Surgery LSUHSC-S

Mark Smith, M.D.	2010	American Cancer Society/LA. Cancer Competition Award
Mark Smith, M.D.	2010	Best Resident Presentation Award-Department of Surgery LSUHSC-S
Catherine Parker, M.D.	2010	Best Resident Presentation Award-Department of Surgery LSUHSC-S
David Hiller	2011	-Winner of the Association for Academic Surgery (AAS) Student Research Award -Outstanding Surgery Student Award -Dr. Adrian F. Reed Award -John McDonald Award
Ashley Arnold	2011	-Finalist for AAS
Catherine Parker, M.D.	2011	-Winner of Best Oral Presentation at LA-ACS & SAL Annual Meeting -Best Resident Basic Research Presentation Award-Department of Surgery LSUHSC-S
Amanda Henderson	2011	-Winner of Best Poster Presentation at LA-ACS & SAL Annual Meeting -Finalist for Resident Research Presentation Department of Surgery LSUHSC-S
Alireza Jahromi	2012	-Winner of American Cancer Society/LA. Cancer Competition Award --Best Oral Presentation at IHPBA in Paris
Catherine Parker, M.D.	2012	--Winner of Resident Research Presentation Department of Surgery LSUHSC-S --Fellow at M.D. Anderson Cancer Center
Amanda Henderson	2012	-Finalist for Resident Research Presentation Department of Surgery LSUHSC-S
Ariel Dubose	2013	-Finalist for Resident Research Presentation Department of Surgery LSUHSC-S
Beth Townsend	2013	Finalist for Resident Research Presentation Department of Surgery LSUHSC-S
Ariel Dubose	2014	Finalist for Resident Research Presentation Department of Surgery LSUHSC-S

Beth Townsend	2014	Finalist for Resident Research Presentation Department of Surgery LSUHSC-S
Nick Harris	2014	Resident Research Presentation Department of Surgery LSUHSC-S
Alireza Jahromi	2014	Winner of Best Cancer Paper Competition Annual LA-ACS Surgical Meeting
Beth Townsend	2015	Winner of Resident Research Competition Department of Surgery LSUHSC-S
Kaelen Medeiros	2016	First Place Best Cancer Paper Competition Annual LA-ACS Surgical Meeting
Meijiao Zhou	2016	Second Place Best Cancer Paper Competition Annual LA-ACS Surgical Meeting
Conner McDaniel	2017	Winner of Best Cancer Paper Competition Annual LA-ACS Surgical Meeting Finalist of Surgery Research Paper
Lloyd Jones	2017	Finalist of Surgery Research Paper
Rachel Shirley	2017	Finalist of Surgery Research Paper
Alireza Jahromi	2017	2 nd Place Winner of Best Oral Paper Competition Annual LA-ACS Surgical Meeting 1 st Place Winner of Best Research Paper Department of Surgery LSUHSC-S
Mei-Chin Hsieh	2021	Winner of Best Cancer Paper Competition Annual LA-ACS Surgical Meeting
Tingting Li	2021	3 rd place for Best Cancer Paper Competition Annual LA-ACS Surgical Meeting
Lauren Geisel	2022	1 st Place Winner of Best Cancer Paper Department of Surgery-Orlando Health

RESEARCH FUNDING:

1. Agency: **Feist-Weiller Cancer Grant** Amount: \$20,000

- Title: The Role of Gene Therapy in a Rat Peritoneal Carcinomatosis Model
 Role: Principal Investigator Effort: 20%
 Period of Grant: 1/06-1/07
2. Agency: **Susan G. Komen Foundation** Amount: \$95,436
 Title: Patient Navigation Program for Breast Cancer
 Role: Principal Investigator Effort: 10%
 Period of Grant: 4/09-3/2010
3. Agency: **Vietnam Education Foundation** Amount: \$55,000
 Title: Fundamentals of General Surgery
 Role: Principal Investigator Effort: 20%
 Period of Grant: 9/09-6/2010
4. Agency: **LA Gene Therapy Consortium** Amount: \$25,000
 Title: CRAd-CXCR4-UTR-E1a.Fiber5/3s in In Vitro and In Vivo Model of Pancreatic Cancer
 Role: Principal Investigator Effort: 10%
 Period of Grant: 7/09-6/2010
5. Agency: **Pharmaceutical Companies** Amount: \$13,000
 Title: 16th Annual Carroll W. Feist Scientific Symposium on Hepatocellular Carcinoma
 Role: Program Director Effort: 20%
 Period: 7/17/2009
6. Agency: **Pharmaceutical Companies** Amount: \$14,000
 Title: 1st Annual Regional Hepato-Pancreato-Biliary Symposium on Pancreatic Carcinoma
 Role: Program Director Effort: 20%
 Period: 11/20/2009
7. Agency: **Pharmaceutical Companies** Amount: \$14,000
 Title: 17th Annual Carroll W. Feist Scientific Symposium on Esophageal Carcinoma
 Role: Program Director Effort: 20%
 Period: 7/23/2010
8. Agency: **Department of Defense** Amount: \$75,000
 Title: Integrin ($\alpha 6\beta 4$) Regulation of Lipid Rafts Signaling
 Role: Co-Investigator Effort: 20%
 Period: 5/2010 through 5/2011
9. Agency: **Vietnam Education Foundation** Amount: \$55,000

Title: Multidisciplinary Approach in Managing Breast Cancer

Role: Principal Investigator

Effort: 20%

Period: 10/25/2010-3/31/2011

10. Agency: **R01 CA 112282-06A1**

Title: The Role of CDC25A in Breast Cancer

Role: Co-Investigator

Effort: 5%

PI: Hiroaki Kiyokawa, Ph.D.

Amount: \$1,375,937

Period: 7/1/11-6/30/13

EDITORIAL DUTIES:

1. NIH Challenge Grant Reviewer 2009
2. Editorial Board:
 - a. Surgery
 - b. Virus, Adaptation and Treatment
 - c. Global Journal of Surgery
 - d. Louisiana State Medical Society
 - e. Surgery: Open Access
 - f. Scientifica
 - g. Journal of Tumor
3. Invited Editor
 - a. Lead Guest Editor for International Journal of Breast Cancer
 - b. Lead Guest Editor for Journal of Gastrointestinal Oncology
4. Reviewer
 - a. Breast Cancer Research and Treatment
 - b. Annals of Surgical Oncology
 - c. Surgery

- d. Journal of the American College of Surgeons
- e. Journal of Surgical Research
- f. World Journal of Surgery
- g. Journal of Cellular and Molecular Medicine
- h. AAMC MedEdPORTAL Reviewer
- i. BioMED Central
- j. European Journal of Obstetrics and Gynecology and Reproductive Biology
- k. The Breast
- l. Canadian Journal of Surgery
- m. Journal of the Pancreas
- n. Community Oncology
- o. Advanced Drug Delivery Reviews
- p. Journal of Surgical Oncology

REFEREED PUBLICATIONS (Articles, Abstracts, and Proceedings):

1. **Chu Q.D.** The Jigsaw Puzzle. *The Rhode Island Medicine* 1994;77:68-9.
2. Chougule PB, Suk S, **Chu Q.D.**, Leone L, et al. The Role of Cis-Platinum as a Potent Radiation Sensitizer in the Treatment of Advanced Head and Neck Cancers: Result of a Phase II Study. *Cancer* 1994;74:1927-32.
3. **Chu Q.D.**, Vezeridis M, Libbey N, Harold J. Wanebo. Giant Condyloma Acuminatum (Buschke-Loewenstein Tumor) of the Anorectal and Perianal Regions: Analysis of 42 Cases. *Diseases of the Colon and Rectum* 1994;37:950-7.
4. **Chu Q.D.**, Medeiros LJ, Fisher A, Crowley J. Thrombotic Thrombocytopenic Purpura (TTP) and HIV Infection. *Southern Medical Journal* 1995;88:82-6.
5. **Chu Q.D.**, Shraye DP, Wanebo HJ. Biphasic effect of cisplatin and taxol on B16 F10 melanoma cells. *Proceedings of the 86th Annual Meeting of the American Association for Cancer Research* 1995;36:2218.
6. Wanebo HJ, **Chu Q.D.**, Avradopoulos KA, Vezeridis MP. Current Perspectives on Repeat Hepatic Resection for Colorectal Carcinoma: A review: *Surgery* 1996; 119:361-71.
7. Wanebo HJ, **Chu Q.D.**, Vezeridis MP, Soderberg C. Patient Selection for Hepatic Resection for

- Colorectal Metastases. *Archives of Surgery* 1996; 131:322-9.
8. **Chu Q.D.**, Simon B, Emhoff T, Fiallo V, Lee KF. Age, Mechanism of Injury, and Injury Severity Score as Predictors of Financial Outcome in Regional Pediatric Trauma Care: A New Outcome-Based Injury-Prevention Strategy. *Surgical Forum Vol 47*: 1997;643-6.
 9. **Chu Q.D.**, Vezeridis M, Avradopoulos KA, Wanebo HJ. Repeat Hepatic Resection for Recurrent Colorectal Cancer. *World J Surg* 1997;21:292-6.
 10. Simon B, **Chu Q.D.**, Emhoff T, Fiallo V, Lee KF. Delayed hemothorax following blunt thoracic trauma. An uncommon entity with significant morbidity: *J Trauma* 1998; 45:673-6.
 11. **Chu Q.D.**, James Petros. Extraperitoneal rectal perforation due to retroflexion fiberoptic proctoscopy. *American Surgeon* 1998;65:81-5.
 12. Tehrani HY, Petros JG, Kumar RR, **Chu Q.D.** Markers of severe appendicitis. *American Surgeon* 1999; 65:453-5.
 13. **Chu Q.D.**, Hill H, Wiseman S, Loree T, Rigual N, Hicks W. Squamous cell carcinoma of the lip Nodal stage remains the most accurate predictor of outcome for stage III/IV disease. *American Head and Neck Society* 2001
 14. **Chu Q.D.**, Smith J, Nava H, Douglass H, Driscoll D, Gibbs JF. Neuroendocrine tumor of the pancreas. The Roswell Park Experience. *Ann Surg Oncol* 2002; 9: 101.
 15. **Chu Q.D.**, Smith J, Nava H, Douglass H, Gibbs J. Phase II trial of infusional 5-fluorouracil, mitomycin C, and external beam radiation followed by pancreatectomy for patients with locally advanced adenocarcinoma of the pancreas. A long-term follow-up. *Proceedings of American Society of Clinical Oncology* 2002; 21: A2304.
 16. Gibbs J, Penetante R, Martinick M, **Chu Q.D.**, Driscoll D, Hurd T, Markus G, Harvey S. Immunohistochemical evaluation of urinary plasminogen activator (uPA), its receptor (uPAR), matrixmetalloproteinases-9 (MMP-9) and von Willebrand factor (vWF) in pancreatic cancer. *Proceedings of the American Association Cancer Research* 2002; 43: A1974.
 17. Wiseman S, Hicks W, **Chu Q.D.**, Rigual NR. Sentinel lymph node biopsy in staging of differentiated thyroid cancer: A critical review: *Surg Onc* 2002;11:1-8.
 18. Donias HW, **Chu Q.D.**, Anderson TM, Karamanoukian RL, Gibbons WJ, Karamanoukian HL. Bronchogenic cysts presenting as thymic cysts. *Contemporary Surg* 2002;58:562-5.
 19. Wiseman S, **Chu Q.D.**, Hicks W, Rigual NR, Popat S, et al. Patient characteristics and treatment outcome of parathyroid carcinoma. *Otolaryngology-Head and Neck Surgery* 2002;127:115.
 20. **Chu Q.D.**, Davidson R, Rodriguez-Bigas M, Wirtzfeld D, Petrelli N. Is abdominoperineal resection a good option for stage IV adenocarcinoma of the distal rectum? *J Surg Onc* 2002;81:3-7.
 21. **Chu Q.D.**, Hill H, Smith J, Nava H, Douglass H, Driscoll D, Gibbs. Predictive factors associate with long term survival in patients with neuroendocrine tumor of the pancreas. *Ann Surg Onc* 2002;9:855-62.
 22. **Chu Q.D.**, Al-kasspooles M, Smith J, Nava H, Douglass H, Driscoll D, Gibbs J. Is glucagonom of the pancreas a curable disease? *International Journal of Pancreatology* 2002: 29:155-62.
 23. **Chu Q.D.**, Hurd T, Harvey S, Martinick M, Penetrante R, Hicks W, Rigual N, Loree T. Urinary plasminogen activator (uPA) is expressed in papillary thyroid carcinoma but not in benign thyroid tumor. *Annual Meeting of American Head and Neck Society* 2002, pg. 34.
 24. **Chu Q.D.**, Smith J, Nava H, Douglass H, Driscoll D, Gibbs JF. Neoadjuvant treatment followed by pancreatectomy for patients with locally advanced adenocarcinoma of the pancreas. A long term follow-up. *Current Surgery* 2002;59:577.
 25. **Chu Q.D.**, Smith J, Nava H, Douglass H, Driscoll D, Gibbs JF. Aggressive treatment associated

with long-term survival in patients with neuroendocrine tumor of the pancreas. *Current Surgery* 2002;59:578.

26. **Chu Q.D.**, Khushalani N, Javle M, Douglass H, Gibbs J. Should adjuvant therapy remain standard of care for patients with resected adenocarcinoma of the pancreas? *Ann Surg Onc* 2003;10:539-45.
27. McClusky, D., Gauthier, M., Meschonat, C., **Chu, Q.**, Li, B.D.L. High eIF4E Predicts Cancer Recurrence in Node-positive Breast Carcinoma. *Proceedings of the American Association for Cancer Research*, 44:297, 2003.
28. McClusky, D., Gauthier, M., Meschonat, C., **Chu, Q.**, Alley, J.A., Sehon, K., Johnson, L.W., Li, B.D.L. High eIF4E Predicts Recurrence in Node-negative Breast Cancer Patients. *Proceedings of the American Society for Clinical Oncology*, 22:851, 2003.
29. Ethridge, L., Macynski, M., **Chu, Q.**, McClusky, Turnage, R., Li, B.D.L. Referral to American Cancer Society May Not Improve the Quality of Life for Patients with Breast Cancers. *Proceedings of the Lynn Sage Breast Cancer Symposium* 5:B7, 2003.
30. **Chu, Q.D.**, Turnage, R.H., Burton, G., Ampil, F., McDonald, J.C., Li, B.D.L. Neoadjuvant Chemotherapy Attenuates the Overexpression of eIF4E in Patients with Breast Carcinomas. *Proceedings of the 2nd Annual AACR Frontiers in Cancer Prevention Research* 2:86-87, 2003.
31. Hoshi H, Foster J, **Chu Q.D.**, Kuvshinoff B, Rajput A, Nava H, Gibbs J. Radical resection is indicated for all T2 and T3 gallbladder cancers and results in the same survival as primarily resected gallbladder cancers. *Annals of Surg Onc* 11 (2): 98, 2004
32. **Chu, Q.D.**, D. McClusky, Turnage, R.H., Johnson, L.W., McDonald, J.C., Li, B.D.L. Impact Of eIF4E Overexpression On Survival In Advanced Breast Cancer. *Annals of Surg Oncol* 11(2): 42, 2004.
33. **Chu, Q.D.**, Turnage, R., McClusky, D., Meschonat, C., Li, B.D.L. Overexpression of Eukaryotic Initiation Factor 4E (eIF4E) in Soft Tissue Neoplasms. *Proceedings of the AACR* 45:4285, 2004.
34. **Chu, Q.D.**, Johnson, L.W., Li, B.D.L. Management of Retroperitoneal Sarcoma. *Journal of the LA State Medical Society* 156(2):95-98, 2004.
35. White, S., Ampil F., Burton G., Li B.D.L., **Chu Q.D.** Is Breast Conservation an Acceptable Alternative for Breast Cancer Patients with Collagen Vascular Diseases? *Annals of Surg Oncol* 11(2): 43, 2004.
36. Wolfort, R.M., Li, B.D.L., Ramaswamy, M., Turnage, R.T., Ampil, F., Burton, G., **Chu, Q.D.** The Role of Positron Emission Tomography in the Detection of Metastasis in Symptomatic Patients with Stage II and III Breast Cancer. *Proceedings of the ASCO* 23:56, 2004.
37. Connor, M.S., Li, B.D.L., Ramaswamy, M., Turnage, R.T., **Chu, Q.D.** PET-Positive Thyroid Incidentalomas: Characteristics and Risks of Malignancy Observed in a Tertiary Referral Center. *Proceedings of the ASCO* 23:495, 2004.
38. Alassas M, **Chu QD**, Burton GV, Ampil F, Li BDL. Impact of Neoadjuvant Therapy on Stage III Breast Cancer Outcome. *Southeastern Surgical Association* 2004
39. **Chu QD**, Li J, Byrnes K, McClusky D, Okadata Y, De Benedetti A, Mathis M, Turnage R, Li BDL. A Translational Restricted HSV-TK/GCV Gene Increases Disease-Free and Overall Survival in a Minimal Residual Rat Breast Cancer Model. *J Surg Research* 2004;121:280.
40. Byrnes K, Li J, **Chu QD**, Mathis M, Sibley D, Odaka Y, De Benedetti A, Turnage R, Li BDL. Using an Ad-HSV-UTK Gene Construct to Exploit eIF4E Overexpression in Tumor Cells to Improve Outcome. *Society of University Surgeons* 2005; 110:A66
41. Vazquez, S, Byrnes, K, **Chu, Q.D.**, Cole, P, Li, B.D.L, Stratton, M. Eukaryotic Initiation

- Factor 4E (eIF4E) Expression in Malignant Versus Inflammatory Colon Tissue. *Ann Surg Onc* 2005;S12:A167
42. Byrnes KW, Li B, Ampil F, Burton G, Abbas M, Johnson L, **Chu QD**. Effect of neoadjuvant chemotherapy on eIF4E expression in breast carcinoma. *Ann Surg Onc* 2005;S12:A101.
 43. **Chu QD**, Hurd TC, Harvey S, Martinick M, Markus G, Tan DF, Gibbs JF, Loree T. Overexpression of Urinary Plasminogen Activator (uPA) Protein and mRNA in Thyroid Malignancies. *Diagnostic Molecular Pathology* 2004;13:241-246.
 44. Byrnes K, Norton K, **Chu QD**, Yu H, Johnson L, Sehon K, Alley J, Meschonnet C, Abbas M, Li B. Eukaryotic initiation factor 4E elevation increases risk for cancer recurrence and death in node-negative breast cancer patients. DoD 2005
 45. Ampil F, Burton G, Li BDL, **Chu Q**, Krishnamsetty RM, Caldito G. Thoracic metastases from breast cancer: A single-institution's experience. *Eur J Gynaec Onc* 2005;26:155-7.
 46. Alassas M, **Chu Q**, Burton G, Ampil F, Mizell J, Li BDL. Neoadjuvant chemotherapy in stage III breast cancer. *American Surgeon* 2005;71:487-92.
 47. Zibari G, Byrnes K, Whitlock M, **Chu QD**, Maley W, Lilian D, Johnson L, McDonald JC, Turnage R. FDG-PET is Superior to CT Scanning for Detecting Hepatic Recurrence in Liver Resection Patients. *Southern Surgical Association* 2005.
 48. Byrnes K, White SC, Abreo F, Yu H, Meschonnet C, Johnson L, **Chu Q**, Turnage R, Li B. eIF4E overexpression, angiogenesis, and breast cancer outcome. *Southern Surgical Association* 2005.
 49. Hoshi H, Foster J, **Chu Q.D.**, Smith JL, Driscoll D, Nava HR, Gibbs JF. Results of Radical resection for T2 and T3 gallbladder cancers. *Ann Surg Onc* 2004
 50. Wolfort RM, Byrnes KW, Li DLB, Turnage RH, Lilien D, **Chu QD**. The Role of Positron Emission Tomography in the Evaluation of Local Recurrence and Distant Metastasis in Stage III Breast Cancer Patients. *ASCO* 2005.
 51. Kleiner HE, Campbell CTD, Prince M, Robertson TA, Krishman P, Li DL B, **Chu QD**. Anticarcinogenic effects of citrus Auraptene on rat breast cancer. 28th Annual San Antonio Breast Cancer Symposium 2005.
 52. Wolfort RM, **Chu QD**, Turnage RH, Yu H, Nuthalapaty S, DeBenedetti A, Li DL B. Upregulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated breast cancer patients. *JSR* 2006;130:218.
 53. Byrnes, K.W., Li, B.D.L., Li, J., Turnage, R., **Chu, Q**. Apoptosis in a Malignant Cell Line Induced by a Novel Suicide Gene Therapy Exploiting Elevated Levels of Eukaryotic Initiation Factor 4E. *JSR* 2006;130: 256
 54. Byrnes KW, DeBenedetti A, Holm N, Luke J, Nunez J, **Chu Q**, Meschonnet C, Abreo F, Johnson LW, Li BDL. Correlation of TLK1B Elevation and Recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression. *Transactions of the Southern Surgical Association* 2006;118:173-82.
 55. Byrnes K, White S, **Chu Q**, Meschonnet C, Yu H, Johnson LW, DeBenedetti A, Abreo F, Turnage R, McDonald JC, Li BDL. High eIF4E, VEGF, and Microvessel density in stage I to III breast cancer. *Transactions of the Southern Surgical Association* 2005;117:129-137
 56. White, S.C., **Chu Q.**, Gruner J.S., Abreo, F.W., Yu,H., Johnson, L.W., Li, B.D.L. eIF4E Overexpression, Angiogenesis, and Breast Cancer Outcome. *Southern Surgical Association* 2006
 57. Byrnes K, Hussain U, Li B, Ampil F, Burton G, Turnage R, **Chu QD**. Cost Analysis of Breast Conservation Therapy versus Simple Mastectomy with or without Reconstruction for Patients

- with Ductal Carcinoma In-Situ (DCIS). *Ann Surg Onc* 2006;13:91.
58. **Chu QD**, Connor MS, Lilien D, et al. Positron Emission Tomography (PET) Positive Thyroid Incidentaloma: The Risk of Malignancy Observed in a Tertiary Referral Center. *American Surgeon* 2006;72:272-5.
 59. McClusky D, **Chu QD**, Yu H, DeBenedetti A, Johnson LW, Meschonat C, Turnage R, McDonald J, Abreo F, Li BDL. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. *Ann Surg* 2005;242:584-92.
 60. Wolfort R, Li BDL, Johnson LW, Turnage RH, Lilien D, Ampil F, Burton G, **Chu QD**. The role of whole-body fluorine-18-FDG Positron Emission Tomograph (FDG-PET) in the detection of recurrence in symptomatic patients with stage II and III breast cancer. *World J Surgery* 2006;30:1-6
 61. Byrnes K, White S, **Chu QD**, Meschonat C, Yu H, Johnson L.W., DeBenedetti A., Abreo F., Turnage R, McDonald J. C., Li B.D.L. High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast Cancer. *Annals of Surgery* 243(5):684-692, 2006.
 62. Wolfort, R., **Chu, Q.D.**, Turnage, R.H., Yu, H., Nuthalapaty, S., DeBenedetti, A., Li, B.D.L. Upregulation of TLK1B by eIF4E Overexpression Predicts Cancer Recurrence in Irradiated Patients With Breast Cancer. *Surgery* 2006;140:161-9.
 63. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, **Chu Q**, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. *Ann Surg Onc* 2007;14:128-33.
 64. Byrnes K, Li B, Li J, Mathis M, DeBenedetti A, Odaka Y, Nedeljkovic-Kurepa A, **Chu QD**. A novel suicide gene therapy targeting the overexpression of eukaryotic initiation factor 4E improves survival in a rat model of peritoneal carcinomatosis. *JSR* 2007;137:228.
 65. Holm N, Byrnes K, Li B, Turnage R, Mathis J, **Chu QD**. High chemokine receptor CXCR4 in cancer specimens predicts recurrence in HER-2 negative breast cancer. *JSR* 2007;137:176.
 66. Holm N, Byrnes K, Luke J, **Chu QD**, Li BDL. Risk for residual cancer after a margin-positive biopsy. *Ann Surg Onc* 2007;14:82 (P168).
 67. Foster J, Hoshi H, Gibbs J, Iyer R, Javle M, **Chu Q**, Kusvshinoff B. Gallbladder cancer: defining the indications for primary radical resection and radical re-resection. *Ann Surg Onc* 2007;14:833-40.
 68. Ampil F, Burton G, Caldito G, Li B, **Chu QD**. Long Bone Metastases in breast cancer: experience of 47 patients. *Chin J Clin Oncol* 2007;Supple:pg 17.
 69. Holm N, Byrnes K, Siegele B, Li B, Odaka Y, Mathis M, **Chu QD**. A novel conditionally replicative adenovirus gene therapy targeting overexpression of chemokine receptor CXCR4 in a pancreatic cancer cell line. *HPB* 2007;9: Suppl (1): 70
 70. Byrnes K, Holm N, Siegele B, Li B, Mathis M, Odaka Y, **Chu QD**. A novel suicide gene therapy regimen targeting the overexpression of eukaryotic initiation factor 4E in a pancreatic cancer cell line. *HPB* 2007;9: Suppl (1):46
 71. Byrnes K, DeBenedetti A, Holm N, Luke J, Nunez J, **Chu QD**, Meschonat C, Fleurette A, Johnson L, Li BDL. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression. *J Am College Surg* 2007;204:925-34.
 72. Holm N, Byrnes K, Li B, Turnage R, Abreo F, Mathis J, **Chu QD**. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.

JSR 2007;141:53-9.

73. Holm N, Byrnes K, McDonald M, Abreo F, Ampil F, Sanders M, Burton G, Li B, **Chu QD**. Overexpression of Chemokine Receptor CXCR4 in Cancer specimens following neoadjuvant chemotherapy predicts outcome in patients with locally advanced breast cancer (LABC). *J Clin Oncol* 2007;25(18S):584s.
74. **Chu Q.D.**, Sun L, Byrnes, K.W., Li, J., Turnage, R., Li B.D.L. Apoptosis in a Malignant Cell Line Induced by a Novel Suicide Gene Therapy Exploiting Elevated Levels of Eukaryotic Initiation Factor 4E. *J Surg Research* 2007;143: 189-194.
75. Byrnes K, Li B, Holm N, Li J, Okadata Y, De Benedetti A, Mathis M, **Chu Q**. A novel suicide gene therapy targeting the overexpression of eukaryotic initiation factor 4E improves survival in a rat peritoneal carcinomatosis model. *Surgery* 2007;142:270-5.
76. Ampil FL, Sanders ME, Caldito G, **Chu Q**, Burton GV, Li BDL Li. Long bone metastases in breast cancer: Experience of 47 patients. Proc 4th Congress of the World Society for Breast Health 2007.
77. Holm N, Li B, Turnage R, Johnson L, **Chu Q.D**. Chemokine Receptor CXCR4 overexpression predicts recurrence for hormone-receptor positive, node-negative breast cancer patients. *J Surg Res* 2008;144(2):319.
78. Siegle B, Cefalu C, Holm N, Sun G, **Chu Q**, Tubbs J, Meschonat C, et al. Translation initiation factor eIF4E targeted suicide gene therapy following cytoreductive surgery improves disease-free survival in a mouse soft tissue metastasis model for head and neck squamous cell carcinoma. 3rd Annual Academic Surgical Congress 2008, p. 246 Abstract # 156
79. **Chu QD**, Tubbs J, Robertson T, et al. Hypoxia induces CXCR4 overexpression in pancreatic cancer cells. *AACR* 2008; #4472.
80. Holm N, Abreo F, Johnson L, Li B, **Chu QD**. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). *Breast Cancer Research & Treat* 2009;113:293-9.
81. Ampil FL, Abreo F, Baluna RG, Caldito G, Burton GV, Li BDL, **Chu Q**. Cancerization of the lobules with pre-invasive or early invasive carcinoma of the breast: Management and outcome study. Proc of UICC World Cancer Congress 2008.
82. Holm N, Johnson L, Li B, **Chu Q**. Overexpression of chemokine receptor CXCR4 in cancer specimens predicts outcome in patients with triple-negative breast cancer. *Proceedings of the Journal of Clinical Oncology* 2008;26 (15S):593s #11064.
83. Holm H, Byrnes K, Sehon K, Johnson LW, Alley J, Meschonat C, **Chu Q**, Li BDL. eIF4E overexpression, cancer recurrence, and death in node-negative breast cancer. *Ann Surg Onc* 2008;15(S2):24.
84. Holm N, Byrnes K, Johnson L, Abreo F, Sehon K, Alley J, Meschonat C, **Chu Q**, Li BDL. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer. *Ann Surg Onc* 2008;15:3207-3215.
85. Ampil F, Abreo F, Li B, Baluna R, Burton G, **Chu Q**. Management of cancerisation of the lobules with pre-invasive or invasive breast carcinoma: a case series. *J Radiotherapy in Practice* 2008 (7):229-31.
86. Siegle B, Cefalu C, Holm N, Sun G, Tubbs J, Meschonat C, Odaka Y, DeBenedetti A, Ghali G, **Chu Q**, Mathis J, Li BDL. eIF4E targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival. *J Surg Research* 2008;148:83-9

87. Barnidge M, Veal R, Rau B, **Chu Q**, Behm W, D'Agostino H. Management of postoperative chylothorax utilizing percutaneous CT-guided drainage. *J Louisiana State Med Soc* 2008;160:221-4.
88. Hiller D, **Chu QD**, Meschonat C, Panu L, Burton G, Li B. Reduction in eIF4E level correlates with improved breast cancer outcome in patients treated with neoadjuvant chemotherapy. *J Surg Research* 2009;151:260.
89. Flowers A, **Chu QD**, Panu L, Caldito G, Meschonat C, Li B. Eukaryotic initiation factor 4E (eIF4E) overexpression in triple-negative breast cancer and clinical outcome. *J Surg Research* 2009;151:179.
90. Pennington K, Jung J, Nedeljkovic-Kurepa A, Li BDL, Mathis JM, **Chu QD**. Testing an oncolytic adenovirus for cancer therapy using a novel ex vivo tissue slice model system. *J Surg Research* 2009;151:287.
91. **Chu QD**, Smith M, Williams M, Panu L, Li B.D., Glass J. Race has no impact on breast cancer outcome: Results of 803 patients treated at a public hospital. *AACR 2009*
92. **Chu QD**, Mizell J, Panu L, Johnson L, Ampil F, Turnage R, Li BDL. Elevated Level of CXCR4 in Primary Tumors of HER-2 Negative Breast Cancers Portends a Poor Disease-Free Survival: A Validation Study. *Ann Surg Oncol* 2009;16(S1):57.
93. Smith M, Cole P, **Chu Q**, Li BD. SIRT 1 Expression and Colon Cancer. *Ann Surg Oncol* 2009;16(S1):86.
94. Smith M, Li BD, Sun G, **Chu QD**. CXCR4 expression is not associated with HER-2 status or mTOR expression levels. *ASCO 2009*
95. Kleiner H, Krishnan P, Tubbs J, Smith M, Meschonat C, Shi R, Lowery-Nordberg M, Adegboyeaga P, Unger M, Cardelli J, **Chu Q**, Mathis J, Clifford J, DeBenedetti A, Li B. Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer. *J Experimental & Clin Cancer Res* 2009;28:54 doi: 10.1186/1756-9966-28-5.
96. Flowers A, **Chu QD**, Panu L, Meschonat C, Caldito G, et al. Eukaryotic initiation factor 4E overexpression in triple-receptor breast cancer predicts a worse outcome. *Surgery* 2009;146:220-6.
97. Mizell J, Panu L, Johnson L, Ampil F, Turnage R, Li BDL, **Chu QD**. Overexpression of CXCR4 in Primary Tumor of Patients with HER-2 Negative Breast Cancer was Predictive of a Poor Disease-Free Survival: A Validation Study. *Ann Surg Oncol* 2009;16:2711-16.
98. **Chu QD**, Smith M, Williams M, Panu L, et al. Race/ethnicity has no effect on outcome for breast cancer patients treated at an academic center with a public hospital. *Cancer Epidemiol Biomarkers Prev* 2009;18:2157-61.
99. **Chu QD**, Panu L, Holm N, Li B, Johnson L, Zhang S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. *J Surg Res* 2010;159:689-95. DOI: 10.1016/j.jss.2008.09.020.
100. Hiller D, **Chu Q**, Meschonat C, Panu L, et al. Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer. *J Surg Research* 2009;156:265-9. DOI:10.1016/j.jss.2009.03.060.
101. Smith, M.H., De Benedetti, A., Sun, G., Meschonat, C., Burton, G.V., Caldito, G., **Chu, Q.D.**, Li, B.D.L. Concomitant eIF4E and TLK1B Overexpression in Doxorubicin-treated Breast Cancer. *J Amer. Coll. Surgeons* 209(3S): S119, 2009.
102. **Chu QD**, Pope M, Mathis JM, Sun G, Li B. A novel conditionally replicative adenovirus (Crad) increases infectivity efficiency and oncolytic activity in a human pancreatic adenocarcinoma cell line. 2009 Louisiana Gene Therapy Research Consortium Symposium,

page 36, poster 26.

103. **Chu QD**, Glass J. Findings that hospital factors are surrogate for disparities are misleading. DOI: 10.1200/JCO.2009.26.1107. JCO 2010;28:e56.
104. Grand R, Sun G, Chung J, Meschonat C, Li BD, **Chu QD**. Hypoxia-Inducible Factor-1 α (HIF-1 α) Mediates Chemokine Receptor CXCR4 Expression under Hypoxic Condition in Human Pancreatic Cancer Line CFPAC-1. JSR 2010;158:194.
105. Henderson A, Burton G, Parker C, Ampil F, Li BD, **Chu QD**. Race/Ethnicity Has No Impact on Outcome for Patients with Triple-Receptor Negative Breast Cancer. JSR 2010;158:262.
106. Pennington K, Mathis M, Li BD, **Chu QD**. Testing a tropism-modified conditionally replicative adenovirus for breast cancer in a tissue slice model system. JSR 2010;158:398.
107. Hiller D, Meschonat C, Madumere P, Li B, **Chu QD**. Persistently Elevated Chemokine Receptor CXCR4 in Primary Tumors Following Neoadjuvant Chemotherapy is a Novel Predictive Molecular Marker for Patients with Locally Advanced Breast Cancer. JSR 2010;158:190.
108. Parker C, Smith M, Henderson A, Li BD, Ampil F, **Chu QD**. Breast Conservation Therapy is a Viable Option for Patients with Triple-Receptor Negative Breast Cancer. JSR 2010;158:177.
109. **Chu Q**, Sun G, Li B, Mathis M. Oncolytic activity of a novel conditionally replicative adenovirus (CRAd) against PANC-1 pancreatic adenocarcinoma cells. HPB 2010;12:101.
110. Jafarimehr E, Dabbous H, Zibari G, **Chu Q**, LaRoux S, et al. Major pancreatic surgery, a safe procedure. HPB 2010;12:342.
111. D'Agostino H, Suzuki I, Zibari G, Shokouh-Amiri H, Crow K, Mogghadam S, Veal R, **Chu Q**, et al. Multidisciplinary management of acute pancreatitis complications: experience in 104 patients. HPB 2010;12:423.
112. Pennington K, **Chu QD**, Curiel DT, Li BD, Mathis JM. The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses. J Surg Research 2010; doi:10.1016/j.jss.2010.03.072.
113. **Chu QD**, Burton G, Glass J, Smith M, Li BD. Impact of Race and Ethnicity on Outcomes for Estrogen Receptor-Negative Breast Cancers: Experience of an Academic Center with a Charity Hospital. J Am Coll Surg 2010;210:585-94.
114. Parker C, Ampil F, Burton G, Li B, **Chu QD**. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? Surgery 2010;148:386-91.
115. **Chu QD**, Holm N, Madumere P, Johnson L, Abreo F, Li B. Chemokine receptor CXCR4 overexpression predicts recurrence for hormone-receptor positive, node-negative breast cancer patients. Surgery 2011;149:193-9; doi:10.1016/j.surg.2010.05.016.
116. Li B, Sicard M, Ampil F, Abreo F, Lilien D, **Chu QD**, Burton G. Trimodal therapy for inflammatory breast cancer: a surgeon's perspective. Oncology 2010;79:3-12.
117. Kim R, Li B, **Chu QD**. The role of chemokine receptor CXCR4 in the biologic behavior of human soft tissue sarcoma. Sarcoma 2010. doi:10.1155/2011/593708.
118. **Chu QD**, Nguyen T, McNamara L, Nguyen P, Li B.D, Barish R, Ho H. Is cost the reason for the lack of a sustaining "twinning" surgical program between the U.S. and a developing country? Experience with a university in Vietnam. J Surg Research 2011;165:173.
119. Hiller D, Meschonat C, Kim R, Li BD, **Chu QD**. Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer. J Surg Research 2011;165:179.
120. Pope M, Mathis J, Sun G, Kim R, Li BD, **Chu QD**. CXCR4 tumor specific promoter restricts oncolysis to pancreatic cancer cell lines that overexpress CXCR4. J Surg Research

- 2011;165:304.
121. Pope M, Mathis J, Sun G, Kim R, Li BD, **Chu QD**. A novel modified oncolytic adenovirus Ad5/3-CXCR4 exhibits potent antitumor effect and limited host toxicity against xenograft human pancreatic cancers on SCID mice. *J Surg Research* 2011;165:305.
 122. Kim RH, **Chu QD**, Zibari GB, Eggerstedt JM, Li BD. Prior presentation experience, not education on effective use of PowerPoint, predicts quality of resident research presentations. *J Surg Research* 2011;173.
 123. Arnold A, Caldito G, Rinaudo C, **Chu QD**, Li BD, Eggerstedt J, Kim R. Impact of a program of early clinical exposure on medical students' residency choices of primary care and surgical fields. *J Surg Research* 2011;165:173.
 124. Hiller D, Li B, **Chu QD**. CXCR4 as a predictive marker for locally advanced breast cancer post-neoadjuvant therapy. *J Surg Research* 2011;166:14-8.
 125. Davezac L, Sicard M, **Chu QD**, Kim RH, DeBenedetti A, Li B. High TLK1B Overexpression in breast cancer predicts doxorubicin resistance. *Ann Surg Onc* 2011;18:S53.
 126. Parker C, Johnson L, Panu L, Li B, **Chu QD**. The chemokine receptor CXCR4 as a novel independent prognostic marker for node positive breast cancer patients. *Ann Surg Onc* 2011;18:S65.
 127. Ampil F, Li B, Burton G, Kim R, **Chu QD**, Baluna R. Is baseline bone imaging in high-risk breast cancer patients justified? *Breast Journal* 2012;18(6):639-40.
 128. **Chu QD**, Henderson A, Shokouh-Amiri H, Zibari G. A penrose drain to help reflect the resected "specimen side" jejunum beneath the mesenteric vessels during a pancreaticoduodenectomy. *J Gastrointest Surg* 2011;15:1630-2. DOI: 10.1007/s11605-011-1442-9
 129. Hiller D, **Chu Q**. CXCR4 and axillary lymph nodes: review of a potential biomarker for breast cancer metastasis. *International Journal of Breast Cancer* 2011; Article ID 420981. Doi:10.4061/2011/420981.
 130. Hiller D, **Chu QD**. Current status of Poly(ADP-ribose) Polymerase Inhibitors as novel therapeutic agents for triple-negative breast cancer. *Int J Breast Cancer* 2012;2012, Article ID 829315. Doi:10.1155/2012/829315.
 131. **Chu QD**, Jaganmohan S, Kelly B, Holey J. Verrucous Carcinoma of the Esophagus: A rare variant of squamous cell carcinoma for which a preoperative diagnosis can be a difficult one to make. *J La State Med Soc* 2011;163:251-3.
 132. Hiller D, Meschonat C, Li B, Kim R, **Chu QD**. Chemokine Receptor CXCR4 Level in Primary Tumors Independently Predicts Outcome for Patients with Locally Advanced Breast Cancer. *Surgery* 2011;150:459-65.
 133. Ampil F, **Chu Q**, Caldito G, Li B, Burton G, Kim R, Baluna R. Can "Boost" be avoided in pre-invasive and early breast cancer with free surgical margins after breast conservation surgery and irradiation? *J Radiotherapy in Practice* 2011;10:209-12.
 134. **Chu QD**, Zibari G, Ho H. Surgical Volunteerism in Vietnam: Surgeons and Educators Strengthen the U.S.-Vietnam Relationship. *American College of Surgeons Bulletin* 2011;96:12-18.
 135. Neel, J.D, Meschonat, C., Miller, K., Sicard, A., Kim, R.H., **Chu, Q.D.**, Li, B.D.L. Management of Soft Tissue Sarcoma in a Rural Setting. Program of the Southeastern Surgical Congress, P65, 2012.
 136. Kalsow, S., **Chu, Q.D.**, Kim, R., Li, B.D.L. A Matched Control Study of Survival in African Americans with Advanced Melanoma. Program of the Southeastern Surgical Congress, P64,

- 2012.
137. Smith M, Kim R, Youssef A, Li B, **Chu QD**. Does race/ethnicity, insurance status affect outcome in patients with gunshot wound to the abdomen? *JSR* 2012;172:200.
 138. Jahromi A, Shokouh-Amiri H, Jafarimehr E, **Chu QD**, Wellman G, Shi R, Zibari G. Peripancreatic soft tissue involvement as a novel independent predictor of outcome for patients with resected pancreatic malignancy. *JSR* 2012;172:341.
 139. Zibari G, Hamidian A, Takalkar Q, **Chu QD**, D'Agostino H, Shokouh-Amiri H. Accuracy and impact of PET-CT in the diagnosis and management of pancreatic lesions. *JSR* 2012;172:341.
 140. Gulick J, **Chu QD**, Abreo F, Li B, Kim R. Diagnostic discordance of intraoperative frozen-section pathology at an academic medical center. *JSR* 2012;172:343.
 141. **Chu QD**, Henderson A, Kim R, Miller K, Burton G, Ampil F, Li B. Should a routine metastatic work-up be performed for all patients with N2/N3 breast cancer? *J Am Coll Surg* 2012;214:456-62.
 142. Armaghany T, Wilson J, **Chu Q**, Mills G. Genetic alterations in colorectal cancer. *GI Cancer Research* 2012;5:19-27.
 143. **Chu QD**, Henderson A, Ampil F, Li B. Outcome for patients with triple-receptor negative breast cancer is not dependent on race/ethnicity. *Int J Breast Cancer* 2012. Article ID 764570; doi:10.1155/2012/764570.
 144. **Chu QD**, King T, Hurd T. Triple Negative breast cancer (Editorial). *Int J Breast Cancer* 2012. Article ID 671684. doi:10.1155/2012/671684.
 145. **Chu QD**, Kim R. Immunocompetent orthotopic pancreatic cancer murine model: A step in the right direction. *J Surg Res* 2013;179:52-3, doi:10.1016/j.jss.2011.11.1011.
 146. Parker C, Panu L, Li B, Johnson L, **Chu QD**. The chemokine receptor CXCR4 as a novel independent prognostic marker for node positive breast cancer patients. *J Surg Oncol* 2012;106:393-8. doi: 10.1002/jso.23113.
 147. Martin B, Jahromi A, **QD Chu**, Takalkar A, Sangster G, Zibari G, Shokouh-Amiri H. The Role of CT, PET, PET/CT, and Tumor Marker CA19-9 for Monitoring Recurrence of Pancreatic Adenocarcinoma. 2012 International Hepato-Pancreato-Biliary Association.
 148. Sheng J, Jahromi A, Takalkar A, **Chu QD**, D'Agostino H, Zibari G, Shokouh-Amiri H. The Role of Positron Emission Tomography in the Diagnosis and Staging of Pancreatic Lesion. 2012 International Hepato-Pancreato-Biliary Association.
 149. D'Agostino H, Jahromi H, Jafarimehr E, Johnson P, Fazili A, **Chu QD**, Shokouh-Amiri H, Zibari G. A strategy and guidelines proposal for effective percutaneous drainage of pancreatic collections: Results on 121 patients. *J Louisiana State Med Soc* 2013;165:74-82.
 150. Shokouh-Amiri H, Jahromi A, Jafarimehr E, **Chu QD**, D'Agostino H, Wellman G, Shi R, Zibari G. Curative Resection of the Pancreatic Cancer with Major Venous Resection/Repair is a Safe Procedure. 2012 International Hepato-Pancreato-Biliary Association.
 151. **Chu QD**, Pope M, Sun G, Curiel DT, Li B, Mathis JM. Virotherapy Using a Novel Chimeric Oncolytic Adenovirus Prolongs Survival in a Human Pancreatic Cancer Xenograft Model. *Surgery* 2012;152:441-8.
 152. **Chu QD**, Nguyen T, Nguyen P, Ho H. Cost Analysis of Establishing a Relationship between a Surgical Program in the U.S. and one in Vietnam. *Int Surg* 2012;97:155-160.
 153. Dubose A, **Chu QD**, Li B, Kim R. Is chronic kidney disease an independent risk factor for mortality in breast cancer? *ASC* 2013
 154. Mowald R, Li B, **Chu QD**, Kim R. Does obesity have an impact on outcomes in triple-negative breast cancer? *ASC* 2013

155. Kim R, Gilbert T, Ristig K, Li B, **Chu QD**. Surgical resident learning styles: faculty and resident accuracy at identification of preferences and impact on ABSITE Scores. *J Surg Res* 2013;184:31-6.
156. Ampil F, Caldito G, Henderson B, Li B, Kim R, Burton G, **Chu Q**. Carcinoma of the axillary tail of Spence: a case series. *Anticancer Res* 2012;32:4057-60.
157. Fallahzadeh M, Zibari G, Jahromi A, **Chu QD**, Shi R, Shokouh-Amiri H. Laparoscopic vs open liver resection for benign and malignant solid liver tumors: a case matched study. *J Lap & Adv Surg Tech* 2013;23:1-4.
158. Jahromi A, D'Agostino H, Zibari G, **Chu QD**, Clark C, Shokouh-Amiri H. Surgical versus nonsurgical management of traumatic major pancreatic duct transection. Institutional experience and review of the literature. *Pancreas* 2013;42:76-87.
159. Jahromi A, Fallahzadeh M, Cruz N, **Chu Q**. Epidermoid cyst arising from an intrapancreatic accessory spleen: A case report and a review of the literature. *J La State Med Soc* 2013;165:153-6.
160. **Chu QD**. Surgical Skills Training: Opportunity to Alleviate Surgical Demands. *JSR* 2013;184:790-1.
161. **Chu QD**. 2013 Japan Traveling Fellow reports on experience. *ACS Bulletin* 2013;98:78-82.
162. Jahromi A, Sangster G, Zibari G, Martin B, **Chu Q**, et al. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma. *JOP* 2013;24:466-68.
163. Kim R., **Chu QD**. Pediatric appendectomy: an example of a tailored approach to resident supervision. *JSR* 2013;185:496-7.
164. **Chu QD**. Margin status after lumpectomy: Does surgical method matter? *JSR* 2013;185:537-8.
165. Ampil F, Caldito G, Li B, Devarakonda S, Burton G, Kim R, **Chu Q**. Morbid obesity does not disadvantage patients with in situ or early-stage carcinoma undergoing breast-conserving surgery. *Anticancer Res* 2013;33:3867-9.
166. Yin X, Kim R, **Chu QD**, Miller J, Li B. Overexpression of eIF4E increases risk for systemic dissemination in node-positive breast cancer patients. *Proceedings of the Southern Surgical Association*, 2013.
167. Sugar J, **Chu QD**, Cole P, Li B, Kim R. Effects of January vacations and prior night call status on resident ABSITE performance. *J Surg Ed* 2013.;70: 720-4.
168. Dubose A, **Chu QD**, Li B, Kim R. Is chronic kidney disease an independent risk factor for mortality in breast cancer? *J Surg Res* 2013;184:260-4.
169. Mowad R, **Chu QD**, Li B, Burton G, Ampil F, Kim R. Does obesity have an impact on outcomes in triple-negative breast cancer? *J Surg Res* 2013;184:253-9.
170. Kim R, Gilbert T, Ristig K, **Chu QD**. Surgical resident learning styles: faculty and resident accuracy at identification of preferences and impact on ABSITE Scores. *JSR* 2013;184:31-6.
171. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander H, Attiyeh F, Bartlett D, Bastidas A, Blazer T, **Chu Q**, Chung K, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. *Ann Surg Oncol* 2014;21:1501-5.
172. Jahromi A, Zibari G, Jafarimehr E, **Chu Q**, et al. Peripancreatic soft tissue involvement: independent outcome predictor in patients with resected pancreatic adenocarcinoma. *Int Surg* 2014;99:62-70.

173. Jahromi A, Zibari G, Jafarimehr E, Dabbous H, **Chu Q**, et al. Curative resection of pancreatic adenocarcinoma with major venous resection/repair is safe procedure but will not improve survival. *JOP* 2014;15(5):340-8.
174. Shanafelt T, Gradishar B, Kosty M, Satele D, Chew H, Horn L, Clark B, Hanley A, **Chu Q**, Phippen J, Sloan J, Raymond M. Burnout and career satisfaction among U.S. oncologist. *J Clin Oncol* 2014;32:1-15.
175. **Chu QD**, Sakr H, Sun G, Mathis MJ. Targeting the cMet receptor with a novel oncolytic adenovirus increases infection efficiency and oncolytic activity against human pancreatic adenocarcinoma cells. *HPB* 2014.
176. Zibari G, Fallahzadeh M, Mokhtari N, Jahromi A, **Chu Q**, Abdehou S, Shokouh-Amiri H. Minimally invasive versus open distal pancreatectomy for treatment of pancreatic lesions: a single center experience. *IHPBA*, abstr F033-12, 2014.
177. Kim R, Skweres J, Thomas J, **Chu QD**, Heldmann M, Shokouh-Amiri H, D'Agostino H, Zibari G, Sangster G. Solid Pseudopapillary tumors of the pancreas: radiologic characteristics and surgical outcomes. *IHPBA* 2014.
178. **Chu QD**, Caldito G, Miller J, Townsend B. Postmastectomy radiation (PMRT) for N2/N3 breast cancer: Factors associated with low compliance rate. *J Am Coll Surg* 2015;220:659-69.
179. Cerise A, Hamidian J, Ballard D, **Chu QD**, Youssef A, Pahilan M, Warren P, Samra N. Does the insurance status predict the outcome of the trauma patients with abdominal gunshot wounds? Report from a Level 1 trauma academic center with a public hospital. *Am Surg* 2016;82:25-7.
180. **Chu QD**, Zhou M, Medeiros K, Wu. Positive margins contribute to the survival paradox between stage 2B/C and stage 3A colon cancer. *ASC* 2016. Abstr 70.07
181. Kim RH, **Chu QD**, Caldito GC. "Laparoscopic colectomy for cancer: Improved compliance with guidelines for chemotherapy and survival." Quick Shot Oral Presentation, 11th Annual Academic Surgical Congress, Jacksonville, FL, Feb 2, 2016.
182. Master S, Ravipati H, Patel A, Dwary A, Pasam A, **Chu Q**, Shi R, Burton G. Pre-treatment evaluation of LVEF for breast cancer patients receiving anthracyclines: Is it necessary. *JCO* 2016
183. Medeiros K, Zhou M, Peddi P, Wu X, **Chu QD**. Can radiation therapy adequately address positive surgical margins in elderly women (≥ 70 years) with Stage I, ER+ Breast Cancer. *JCO* 2016.
184. **Chu QD**, Peddi P. Should Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer Be Abandoned? Not So Fast. *Clinical Medicine Insights: Oncology* 2016;10:67-9
185. **Chu QD**, Zhou M, Medeiros K, Peddi P, Kavanaugh M, Wu X. Poor Survival in Stage IIB/C (T4N0) compared to Stage IIIA (T1-2N1, T1N2a) Colon Cancer Persists Even after Adjusting for Adequate Lymph Nodes Retrieved and Receipt of Adjuvant Chemotherapy. *BMC Cancer* 2016;16:460
186. **Chu QD**, Zhou M, Medeiros K, Peddi P. Positive Surgical Margins Contribute to the Survival Paradox between Patients with Stage IIB/C (T4N0) and Stage IIIA (T1-2N1, T1N2a) Colon Cancer. *Surgery* 2016;160:1333-43.
187. **Chu QD**, Sakr H, Mathis JM. Targeting the c-Met receptor with a novel oncolytic adenovirus increases infection efficiency and oncolytic activity against human pancreatic adenocarcinoma

cells. *Ann Virol Res* 2016;2:1014

188. **Chu QD**, Zibari G, Annamalai A. Two Decades of Humanitarian Surgical Outreach and Capacity Building in Kurdistan, Iraq. *ACS Bulletin* 2016;101:33-41.
189. Tan W, **Chu QD**. Risk of Venous Thromboembolism and Delivery Methods for Red Blood Cell Transfusion. *Lancet Hematology* 2016;3:550-1.
190. Ballard DH, Pelliccio N, Rudd J, Caldito G, **Chu QD**, Samra NS. Pediatric pedestrians and bicyclists versus motor vehicle accidents: comparison of injury patterns by mechanism and influence of socioeconomic status. *American Surgeon* 2017;83:165-7.
191. Ballard DH, Pennington GP, **Chu QD**, Samra NS. Resident duty hours and American Board of Surgery In-Training Examination performance. *American Surgeon* 2017;83:151-2.
192. Parsons H, **Chu Q**, Karlitz J, Stevens J, Harlan L. Adoption of sorafenib for the treatment of advanced-stage hepatocellular carcinoma in oncology practices in the United States. *Liver Cancer* 2017;6:216-26.
193. Jones L, **Chu Q**, Samra N, Hu B, Zhang W, Tan T. Evaluating the utilization of prophylactic inferior vena cava filters in trauma patients. *Ann Vascular Surg* 2018;46:36-42.
194. **Chu QD**, Zhou M, Medeiros K, Peddi P, Wu X. Impact of CALGB-9343 Trial and sociodemographic variation of patterns of adjuvant radiation therapy practice for elderly women (≥ 70 years) with stage I, estrogen receptor-positive breast cancer: analysis of the National Cancer Data Base. *Anticancer Research* 2017;37:5585-94.
195. Knowles K, Alattia L, Cheng M, **Chu Q**, Turbat-Herrera E, Herrera G. Synchronous primary tumors of the liver and gallbladder: case report and review of the literature. *Ann Clin Case Reports-Pathology* 2017;2;article 1407.
196. **Chu QD**, Zhou M, Peddi P, Medeiros K, et al. Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma. *HPB* 2017;19:1046-57. <http://dx.doi.org/10.1016/j.hpb.2017.04.017>
197. **Chu QD**, Zhou M, Peddi P, Medeiros K, Wu X. Outcomes in real-world practice are different than cooperative trial for elderly patients with early breast cancer treated with adjuvant radiation therapy. *Surgery* 2018;163:1213-9, <https://doi.org/10.106/j.surg.2018.01.018>.
198. Bhargava P, Haque K, Veal R, Turbat-Herrera E, **Chu Q**, Sangster G, D'Agostino H. Parasitic leiomyoma presenting as an inguinal hernia in a postmenopausal woman. *Radiology Case Report* 2018;13:767-71.
199. Wolfson R, Menger R, **Chu QD**, Sin A. Combined surgical oncology and neurosurgery approach for resection of sacral chordoma. *La State Med Soc* 2018;170:72-5.
200. Zhou M, Peddi P, **Chu QD**. Radiation therapy for positive surgical margins in women ≥ 70 years with stage I, estrogen receptor positive breast cancer. *Anticancer Research* 2018;38:5253-60.
201. Awe A, Ballard D, Burger M, Abrams A, Caldito G, **Chu QD**, Samra N. Innovative teaching strategies for surgery resident education sessions: learner preference of slide-based presentations versus focused study guides. *American Surgeon* 2018;84:e541-3.
202. Sabat J, Hsu C, **Chu Q**, Tan TW. The mortality for surgical repair is similar to ligation in patients with traumatic portal vein injury. *J Vasc Surgery: Venous and Lymphatic Disorders* 2018
203. Ampil F, Sangster G, Caldito G, Richards T, Ngo Y, Kim D, **Chu Q**. Palliative radiotherapy as a treatment for carcinoma invasion of the sacrum. An observational case series study. *Anticancer Research* 2018;38

204. Peddi P, Master S, Dwary A, Ravipati H, Patel A, Pasam A, Katikaneni P, Shi R, Burton G, **Chu QD**. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines. *Breast J* 2018;00:1-7. <https://doi.org/10.1111/tbj.13182>.
205. Sabat J, Hsu C, Samra N, **Chu Q**, Weinkauff C, et al. Length of stay and ICU stay are increased with repair of traumatic superior mesenteric vein injury. *J Surg Res* 2019;242:94-99.
206. Jahromi AH, Zibari GB, Sangster G, **Chu QD**, Ballard DH, Shokouh-Amiri H. Accuracy and clinical implications of preoperative multidetector computed tomography (MDCT) in predicting outcome and resectability in patients with pancreatic adenocarcinoma. *Am Surg* 2019;85(5):e273-4.
207. Briley T, Sobiesk J, **Chu QD**. Pilomatrix carcinoma: A rare hair cell tumor. *American Surgeon* 2020;86:e38-9.
208. Kuy S, Gupta R, Correa R, Tsai R, Vohra S, Henry T, Jarvis L, Kotwal M, Gupta R, Sakran J, Hsu B, Gandhi P, Jha S, Fiedler A, **Chu QD**, Hughes L, et al. Best practices for a COVID-19 preparedness plan for health systems. *NEJM Catalyst*. April 30, 2020. DOI: 10.1056/CAT.20.0108.
209. **Chu QD**, Correa R, Henry T, McGregor K, et al. Reallocating ventilators during the COVID-19 pandemic. Is it ethical? *Surgery* 2020. Online May 7, 2020; <https://doi.org/10.1016/j.surg.2020.04.044>.
210. Gazi R, Lagraff T, **Chu QD**, Annamalai A, Jha S, Smith L, Guthikonda B, Shokouh-Amiri H, Zibari G. Medical Capacity Building in War-Torn Nations: Kurdistan, Iraq as a Model. *JACS* 2020
211. Delafontaine J, Candal R, Ranganath R, White R, **Chu QD**. Cervical esophageal exclusion with temporary suture ligation: a novel technique in the management of esophageal perforations. *Am Surg* 2020;
212. **Chu QD**, Hsieh MC, Chu Y, Lyons J, Kandil E, Corsetti R, White RK, Gnerlich J, Wu XC. Do rural patients with operable breast cancer fare worse than urban patients in Louisiana? Results of the Louisiana cancer consortium. *Surgery* 2020;168:653-61
213. Kuy S, Tsai R, Bhatt J, **Chu QD**, et al. Focusing on vulnerable populations during COVID-19. *Academic Medicine* 2020.
214. **Chu QD**, Li T, Hsieh MC, Yi Y, Gibbs JF, Lyons JM, Wu XC. Positive impact of affordable care act (ACA) Medicaid expansion on Louisiana women with breast cancer. *Cancer* 2021;127:688-99.
215. Gibbs J, Guarneri E, **Chu QD**, Murdoch K, Asif A. Value-based Chronic Care Model Approach for Vulnerable Older Patients with Multiple Chronic Conditions. *J. Gastrointest Oncol* 2020. Doi:10.21037/jgo-20-317.
216. Ranganath R, **Chu QD**. Global Trends in Pancreatic Cancer among Asia-Pacific Population. *J Gastrointest Onc* 2002;
217. Song C, **Chu QD**. A simple method of teaching roux-en-y reconstruction in the operating room. *Am Surg* 2020.
218. McKennan A, **Chu QD**. Pink Ink: Post-mastectomy tattoos, a potential option for patients. *Am Surg* 2020.
219. **Chu QD**, Hsieh M, Lyons J, Wu X. 10-year survival after breast-conserving surgery is better than mastectomy for Louisiana women with early breast cancer: A population-based study. *JACS* 2021;232:607-21.

220. **Chu QD**, Renas Zibari, Thai Lagraff, Anand Annamalai, et al. Shoulder-to-Shoulder Capacity Building with Colleagues in War-Torn Kurdistan, Iraq: An Equal Opportunity, Non-partisan Endeavor. In reply to Demirer and Colleagues. *JACS* 2020.
221. **Chu QD**, Gibbs J, Lyons J, Li T, Hsieh M, Yi Y, Wu X. Data Demonstrating a Lack of Black/White Parity in Breast Cancer Mortality Following Medicaid Expansion. Are the Data Granular Enough to Support This? *JCO Global Oncology* 2021;7:GO.20.00428.
222. Gralow J, Asirwa F, Bhatt A, Bourton M, **Chu Q**, et al. Recommendations from the American Society of Clinical Oncology (ASCO) Academic Global Oncology Task Force. *JCO Global Oncol* 2020;6:1666-73.
223. **Chu QD**, Chu Y, Hsieh M, Lagraff T, et al. Rural residence does not predict outcome for resected pancreatic adenocarcinoma. *HPB* 2020, P-169.
224. Gibbs JF, **Chu QD**. Global GI malignancies: a population health management perspective. *J Gastrointest Oncol* 2020. Doi: 10.21037/jgo-209-gi-12.
225. **Chu QD**, White RK, Gibbs JF. Transfer of emergency general surgery residents. Could the role of insurance status be underestimated? *Surgery* 2020;169:1257-65.
226. Kuy S, Tsai R, Henry T, Correa R, **Chu QD**, et al. Caring for vulnerable populations during the COVID-19 pandemic. *Society of General Internal Medicine*. 2020;43(11):11-14.
227. Lyons J, **Chu QD**, Hsieh MC, Wu XC. Breast-conserving therapy vs mastectomy for early-stage breast cancer: Should we re-evaluate the current treatment paradigm? *JACS* 2021;232:801-2.
228. Stoehr JR, Jahromi AH, **Chu QD**, Zibari GB, Gosain AK. Considerations for Resuming Global Surgery Outreach Programs During and After the COVID-19 Pandemic. *Surgery* 2021;1-6.
229. **Chu QD**, Hsieh MC, Gibbs JF, Wu XC. Social determinants of health associated with poor outcome for rural patients following resected pancreatic cancer. *J Gastrointest Oncol* 2021;doi:10.21037/jgo-20-583.
230. **Chu QD**, Hsieh MC, Gibbs J, Wu XC. Treatment at a high-volume academic research program mitigates racial disparities in pancreatic adenocarcinoma. *J Gastrointest Oncol* 2021;doi.org/10.21037/jgo-20-584.
231. **Chu QD**, Candal R, White RK. A novel and simple method of managing thoracic esophageal perforation: The “ASSIST” approach. *American Surgeon* 2021:
232. **Chu QD**, Hsieh MC, Yi Y, Lyons J, Wu XC. Breast-Conserving Surgery Plus Radiation Yielded Better Outcomes Than Mastectomy for all Subtypes of Early-Stage Breast Cancer: Analysis of Over 200,000 Women. *JACS* 2022.
233. **Chu QD**, Briley T. Case report of a novel technique for fecal diversion. *American Surgeon* 2021.
234. Pellicio N, **Chu QD**. Intraoperative Fluoroscopy-Assisted Localization of Small Bowel Gastrointestinal Bleeding. *American Surgeon* 2021.
235. Lyons J, Danos D, Maniscalco L, Yi Y, Wu X, **Chu QD**. Trends in hepatocellular carcinoma in Louisiana, 2005-2015. *Dialogues in Health*; 2022.
236. Shrestha P, **Chu QD**, Hsieh MC, Yi Y, Peters E, et al. Distance to radiation therapy facility influences surgery type among older women with early-stage breast cancer. *Cancer Medicine* 2022;00:1-11.
237. Laughlin A, Li T, Yu Q, Wu X, Yi Y, Hsieh M, Havron W, Shoup M, **Chu QD**. Impact of Medicaid expansion on breast cancer diagnosis and treatment in southern states. *JACS* 2023;236:838-45.

238. Fa A, Danos D, Maniscalco L, Yi Y, Wu X, Maluccio M, **Chu QD**, Lyons J. Is there really a difference in outcomes between men and women with hepatocellular cancer? *Cancers* 2023,15,2892.
239. Gaffley M, Hsieh M, Li T, Yi Y, Gibbs JF, Wu X, Gallagher J, **Chu QD**. Rural versus urban commuting patients with stage III colon cancer: Is there a difference in treatment and outcome? *Surgical Endoscopy* 2023.
240. Maramara T, Hsieh M, Janjua M, Li T, Wu X, Williams M, Shoup M, **Chu QD**. Adherence rate in ACOSOG Z0011 Based on Breast Cancer Subtype. *JACS* 2024

TEXTBOOKS

Chu Q. Lymph Node Dissections. In: *Mastery of Surgery* 2023.

Chu Q, Suzanne Klimberg, Benjamin Anderson, Charles Balch, Catherine Parker, Florence Dedey, Jane Mendez, Chandrakanth Are. *A Practical Guide to Managing Breast Cancer for Low-Middle-Income Countries*. American College of Surgeons 2019 (**Chief Editor**; Pending).

Henry Pitt, Charles Vollmer, **Quyem Chu**. *AHPB. The First 25 Years*. Beaux Books 2020 (Pending).

Chu Q, Vollmer C, Zibari G, Orloff S, Williams M, Gimenez M. *Hepato-Pancreato-Biliary and Transplant Surgery: Practical Management of Dilemmas*: Beaux Books 2018 (**Chief Editor**).

Chu Q, Gibbs J, Zibari G (Editors). *Surgical Oncology: A Practical and Comprehensive Approach*. New York: Springer 2014 (**Chief Editor**).

Chu Q, Ho H (Editors). *Surgical Care at the District Hospital, the World Health Organization. Medical translation into Vietnamese* 2010 (**Chief Editor**).

CHAPTERS, EDITORIALS, AND OTHER NON-REFEREED PUBLICATIONS:

1. **Chu QD**, Zibari G, Turnage R. Gastric Surgery. In Johnson LR (ed) *Encyclopedia of Gastroenterology* 2004; p. 152-6.
2. Turnage R, Johnson LW, **Chu QD**. Gastric Outlet Obstruction. In Johnson LR (ed) *Encyclopedia of Gastroenterology* 2004; p. 138-140.
3. Turnage R, Johnson LW, **Chu QD**. Marginal Ulcer. In Johnson LR (ed) *Encyclopedia of Gastroenterology* 2004; p. 624-6.
4. Turnage R, Johnson LW, **Chu QD**. Volvulus. In Johnson LR (ed) *Encyclopedia of Gastroenterology* 2004; p. 627-30.
5. **Chu QD**, McDonald JC, Li BDL. Adjuvant Therapy for Patients with Node-Positive Breast Cancer. In Cameron, *Advances in Surgery* 2006; 40:77-98.
6. **Chu QD**, Holm N, Byrnes K, Li BDL. Translational Research in Breast Cancer. *Surgical Oncology Clinics of North America* 2008;17:421-38.
7. Upton B, **Chu Q**, Li BD. Li-Fraumeni Syndrome: The genetics and treatment considerations

- for the Sarcoma and Associated Neoplasms. *Surgical Oncology Clinics of North America* 2009;18:145-56.
8. **Chu QD**. Hue Oncology Program Description. For Health Volunteers Overseas and ASCO November 2010.
 9. ASCO's International Cancer Corps Program Expands to Ethiopia and Vietnam. *ASCO Connection* Oct 2011;28-31.
 10. Williams M, **Chu QD**, Rogers S. Non-traumatic diseases of the spleen. In: Meara J, McClain C, Mooney D, Rogers S, eds. *Global Surgery and Anesthesia Manual. Providing Care in Resource-Limited Settings*. Boca Raton, FL: CRC Press; 2014:147-162.
 11. **Chu QD**, Borazanci E, Sangster G, Kim R, Li B. Pancreatic Adenocarcinoma. *American Cancer Society Textbook of Cancer*.
 12. Kim HR, **Chu QD**, Li B. Gastric Cancer. *American Cancer Society Textbook of Cancer*.
 13. **Chu QD**, Adjepong-Tandoh E, Duda R. Locally Advanced Breast Cancer. In: Chu Q, Gibbs J, Zibari G, eds. *Surgical Oncology: A Practical and Comprehensive Approach*. New York: Springer; 2014:113-140.
 14. **Chu QD**, Kim R. Early Breast Cancer. In: Chu Q, Gibbs J, Zibari G, eds. *Surgical Oncology: A Practical and Comprehensive Approach*. New York: Springer; 2014:61-112.
 15. Kim R, **Chu QD**. Breast cancer in pregnancy. In: Chu Q, Gibbs J, Zibari G, eds. *Surgical Oncology: A Practical and Comprehensive Approach*. New York: Springer; 2014:163-70.
 16. Ketner E, **Chu QD**, Karpeh M, Khushalani N. Gastric cancer. In: Chu Q, Gibbs J, Zibari G, eds. *Surgical Oncology: A Practical and Comprehensive Approach*. New York: Springer; 2014:195-216.
 17. Mafi P, **Chu QD**, Smith R, Gibbs J. Cholangiocarcinoma In: Chu Q, Gibbs J, Zibari G, eds. *Surgical Oncology: A Practical and Comprehensive Approach*. New York: Springer; 2014:257-82.
 18. Amrani S, Polcino M, Rodriguez-Bigas M, **Chu QD**. Colon cancer In: Chu Q, Gibbs J, Zibari G, eds. *Surgical Oncology: A Practical and Comprehensive Approach*. New York: Springer; 2014:353-82.
 19. **Chu QD**, Sangster G, Kulaylat M. Rectal cancer. In: Chu Q, Gibbs J, Zibari G, eds. *Surgical Oncology: A Practical and Comprehensive Approach*. New York: Springer; 2014:411-48.
 20. Kim R, **Chu QD**, Li B. Gastric Adenocarcinoma. *The American Cancer Society Textbook of Clinical Oncology (Prevention to Survivorship)*.
 21. **Chu QD**, Borazanci E, Kim R, Sangster G. Pancreatic Adenocarcinoma. *The American Cancer Society Textbook of Clinical Oncology (Prevention to Survivorship)*.
 22. Hamidian A, Kim R, **Chu QD**, Li B. Small Bowel Cancer. *The American Cancer Society Textbook of Clinical Oncology (Prevention to Survivorship)*.
 23. Emdadi A, Zibari G, **Chu QD**. Liver Hemangioma, Focal Nodular Hyperplasia, and Hepatic Adenoma: How Do I Tell Them Apart and When Should They Be Resected? In: Chu Q, Vollmer C, Zibari G, Orloff S, Williams M, Gimenez M (eds). *Hepato-Pancreato-Biliary and Transplant Surgery: Practical Management of Dilemmas*. Shreveport: Beaux Books 2018;53-66.

24. Zibari G, **Chu QD**. How Should I Manage Retained Common Bile Duct Stone(s) in Patients With and Without a Previous Gastric Bypass? In: Chu Q, Vollmer C, Zibari G, Orloff S, Williams M, Gimenez M (eds). Hepato-Pancreato-Biliary and Transplant Surgery: Practical Management of Dilemmas. Shreveport: Beaux Books 2018;247-60.
25. Mowad R, **Chu QD**. How Should I Manage Gallstone-Related Acute Cholangitis? In: Chu Q, Vollmer C, Zibari G, Orloff S, Williams M, Gimenez M (eds). Hepato-Pancreato-Biliary and Transplant Surgery: Practical Management of Dilemmas. Shreveport: Beaux Books 2018;278-82.
26. **Quyen Chu**. The fight against breast cancer illustrates the health care challenges of women in poverty. The Catalyst: A Journal of Ideas from the Bush Institute 2019.
27. **Quyen Chu**. The fight against breast cancer illustrates the health care challenges of women in poverty. ASCO Post 2019.
28. **Quyen Chu**. Allocating ventilators in times of crisis: A brave new world. ASCO Post, May 25, 2020.
29. **Quyen Chu**, Ashley Abrams, Marjorie Malia, Mariano E. Gimenez, Mallory Williams. AHPBA Textbook. In Pitt H, Vollmer CM, **Chu QD** (editors). AHPBA. The First 25 Years. 2020. Beaux Books Publishing.
30. **Quyen D. Chu**. Inguinal Node Dissection. Fischer's Mastery of Surgery 2022.

CME Questions:

1. **Chu QD**, Kim R. Should a routine metastatic work-up be performed for all patients with pathologic N2/N3 breast cancer? JACS 2012;214:735-6.

INVITED LECTURESHIPS AND PRESENTATIONS:

1. "The Role of Adjuvant Therapy for Patients with Resected Stage II Colon Cancer " Roswell Park Cancer Institute. Buffalo, NY. Sept., 2001.
2. "Adjuvant Therapy is Not Indicated for Patients with Resected Pancreatic Cancer" Roswell Park Cancer Institute. Buffalo, NY. Sept., 2002.
3. "Current Perspectives on Pancreatic Adenocarcinoma" LSUHSC Department of Surgery Grand Rounds, Shreveport, LA 2002.
4. "Management of Retroperitoneal Sarcoma" LSUHSC Department of Surgery Grand Rounds, Shreveport, LA 2003.
5. "Current Perspectives on Gastric Adenocarcinoma" LSUHSC Department of Surgery Grand Rounds, Shreveport, LA, 2004.
6. "Controversies in the Surgical Approach to Colorectal Cancer: Routine Open Colectomy –vs- Laparoscopic Colectomy for Colorectal Carcinoma" 6th Annual Red River Gastrointestinal Conference, Shreveport, LA 2004
7. "Cap-Dependent Translation Control" LSUHSC Dept. of Surgery Grand Rounds, Shreveport, LA, 2004.
8. "Current Surgical Management of Primary and Metastatic Gastrointestinal Carcinoid Tumors"

- 2nd Annual Phoenix Multidisciplinary Cancer Symposium, Phoenix, Arizona, October 8th 2005
9. “Cytoreductive Surgery and Intraoperative Hyperthermic Chemo-Perfusion (IPHC) for the Treatment of Peritoneal Carcinomatosis” Feist-Weiller Cancer Center, Shreveport, LA November 21, 2005
 10. “Current Perspectives on the Management of Esophageal Cancer” LSUHSC Department of Otolaryngology Grand Rounds, Shreveport, LA 2006
 11. “Recurrence in Node-Positive Breast Cancer” LSUHSC Department of Otolaryngology Grand Rounds, Shreveport, LA April 11, 2006
 12. “Management of Recurrent and Locally Advanced Colorectal Cancer” Louisiana Cancer Control Partnership Annual Conference, Baton Rouge, LA 2006
 13. “Management of Recurrent and Locally Advanced Breast Cancer” Louisiana Cancer Control Partnership Annual Conference, Baton Rouge, LA 2006
 14. Moderator for Liver and Biliary Symposia. International College of Surgeons, North American Federation. Reno Nevada, 2008
 15. Discussant for Genetic Determinants of Disease and Outcomes of the 94th Annual Clinical Congress of the American College of Surgeons, San Francisco, CA Oct 12-16, 2008.
 16. Role of Chemokine Receptor CXCR4 in Breast Cancer. 2009 SWOG Spring meeting, April 30 –May 4, 2009.
 17. Moderator for 16th Annual Feist Weiller Cancer Symposium on Hepatocellular Carcinoma. Shreveport, LA July 17, 2009.
 18. Moderator for 1st Annual Hepato-pancreato-biliary Symposium. Shreveport, LA November 20, 2009.
 19. “The Role of a Surgical Oncologist in the Community”. Barksdale Airforce Base, Barksdale, LA., February 25, 2010.
 20. Moderator for 17th Annual Feist Weiller Cancer Symposium on Esophageal Carcinoma. Shreveport, LA July 23, 2010.
 21. Leo W. Jenkins Cancer Center as a Nationally Recognized Center of Excellence. East Carolina University. July 19, 2010.
 22. American College of Surgeons 2011 Annual Meeting. Moderator for the 97th Annual Clinical Congress, “Volunteering: Making Service Happen”. San Francisco, CA , October 23-27, 2011.
 23. Vietnam Education Foundation 2011 Annual Meeting. Invited Speaker “Capacity Building. What Can One Achieve in One Year”. University of Arkansas, AR, January 2-5, 2010.
 24. Vietnam Education Foundation 2011 Annual Meeting. Invited Discussant “Building Leadership Skills”. University of Arkansas, AR, January 2-5, 2010.
 25. Vietnam Education Foundation 2011 Annual Meeting. Invited Discussant “Networking for Success”. University of Arkansas, AR, January 2-5, 2010.
 26. Moderator for Louisiana Chapter of the American College of Surgeons Annual Meeting January 21-23 Annual Meeting, Shreveport, Louisiana.
 27. Moderator for 97th Annual Clinical Congress of American College of Surgeons, “Volunteering: Making Service Happen”. San Francisco, CA , October 23-27, 2011
 28. 2012 Academic Surgical Congress (ASC) Faculty: Oncology 5: Breast Cancer: Moderator. February 16, 2012.
 29. 2012 Academic Surgical Congress (ASC) Faculty: Oncology 7: Tumor Biology: Moderator. February 16, 2012.
 30. 9th Annual Vietnam Education Foundation Fellows and Scholars Conference, “What is a Nation’s Best Asset?” Shreveport, LA January 2-5, 2012

31. 2012 Americas Hepato-Pancreato-Biliary Association Annual meeting: Surgeons as “Ambassadors” through surgical volunteerism. Miami, FL March 7-11, 2012.
32. Invited Speaker for the 2012 Leadership Development Program for ASCO. Chicago, IL June 1, 2012.
33. Invited Speaker at the University of Toledo Medical Center. Benign Hepatopancretico-Biliary Diseases, Toledo, Ohio June 2012.
34. Moderator for 2013 LA-ACS/Sal Annual Meeting. January 12-13, 2013. New Orleans, LA
35. Guest speaker for 113th Annual Congress of Japan Surgical Society. Current perspectives of neoadjuvant and adjuvant therapy for patients with pancreatic cancer, Fukuoka, Japan.
36. Invited discussant for 2013 AHPBA Annual Meeting, February 20-24, 2013, Miami, Florida.
37. Invited discussant for 2013 ASCO Career Development Subcommittee. Chicago, IL June 1, 2013.
38. Invited discussant by Vietnamese ambassador, Education Forum: Moving forward: U.S.-Vietnam Cooperation in Higher Education, April 26, 2013, Washington D.C.
39. Keynote speaker at 17th Annual Youth Excellence Recognition Luncheon for Vietnamese Culture and Science Association (VCSA): August 4th, 2013, Houston, Texas.
40. Invited speaker for the U.S.-Vietnam Open Forum: Promoting Science & Technology Research Collaboration & Innovation. Sponsored by Department of State’s Office of Science & Technology Cooperation. September 23, 2013, Washington, D.C.
41. Committee Organizer for AHPBA for the 3rd Workshop at Managua, Nicaragua
42. Invited moderator for LA-ACS Annual Meeting, New Orleans, LA, January 2014
43. Moderator: American College of Surgeons 2014 Annual Meeting, San Francisco, October 27, 2014: Oncology Care and Screening: How Feasible is it and Why Aren’t Nations Doing it?
44. Invited Speaker at Program 6th Annual Joint Americas HepatoPancreato-Biliary Association, Operation Hope, World Surgical Foundation & the American Kurdish Medical Group Symposium, Duhok-Kurdistan, Iraq, April 9, 2015: Management of Pancreatic Injury.
45. Moderator: American College of Surgeons 2015 Annual Meeting, Chicago, IL, October 8, 2015: The Role/Impact of Telemedicine on Surgical Outreach Programs.
46. Chair/Moderator: 12th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA 2016): Liver: Surgical Outcomes 2: Sao Paulo, Brazil, April 20-23, 2016
47. Moderator: 2016 Clinical Congress of the American College of Surgeons: Washington, DC, October 16-20. Surgeons as Global Health Ambassadors: Implementing Sustainable Change Through Diverse and Collaborative Teams.
48. Keynote speaker: Annual LSUHSC Diversity Matters Celebration April 20, 2017.
49. Moderator: Pancreas Adenocarcinoma: Defining the Standard of Care. AHPBA 2017 Annual Meeting, March 29-April 2, 2017; Miami Beach, Florida
50. Presenter: International Outreach-Working Toward Global HPB Care. AHPBA 2017 Annual Meeting, March 29-April 2, 2017; Miami Beach, Florida
51. Presenter: TexMed 2017 Enhanced Perioperative Recovery and the Future of Surgical Care Conference. “Lancet Commission on Global Surgery: Investing in Surgical Care”. MD Anderson, May 5th 2017, Houston, TX
52. Moderator. LA-ACS Annual Meeting 2017, New Orleans, LA
53. Southern Surgical Association. Invited Discussant, Roanoke, VA 2017
54. Moderator for 2019 AHPBA meeting, Eden Roc, Miami
55. Speaker at Pharmedent 2019, Erbil, Iraq. Management of Breast Cancer During Pregnancy
56. Discussant at 15th Annual National Congress of Vietnam Association Study of Liver Disease

- (VASLD). November 29-30, 2019, Ho Chi Minh City, Vietnam
57. Speaker for Honduras 2017
 58. Panelist for American Cancer Society CAN's 2020 Policy Conference on Health Disparities. October 20, 2020.
 59. Panelist for American Cancer Society CLP Orientation Webinar, October 25, 2020.
 60. Panelist for American Cancer Society CLP Annual Meeting, April 20, 2021.
 61. Invited Visiting Professor to Howard University School of Medicine, May 24, 2021
 62. ASCO Podcast November 2021
 63. Chair, Session on Neoadjuvant Therapy for Resectable Pancreatic Cancer. IHPBA 2022. New York, New York.
 64. Chair, Session on Minimal Invasive Surgery for Pancreas. IHPBA 2022. New York, New York.
 65. Speaker, 3rd PAHPBS International Symposium, December 1-2, 2022. Pasig City, Philippines.
 66. Invited speaker for Grand Rounds at Willis Knighton Medical Center, Shreveport, LA January 10, 2023. Pancreaticoduodenectomy for Distal Cholangiocarcinoma.
 67. Invited speaker for Grand Rounds at Howard University, Washington DC, March 27, 2023. Pancreaticoduodenectomy for Distal Cholangiocarcinoma

PRESENTATIONS AT PROFESSIONAL MEETINGS:

1993

1. Thrombotic Thrombocytopenic Purpura (TTP) and HIV Infection.
American College of Physicians-Rhode Island Scientific Meeting, Providence, RI
2. Metastatic Dermatofibrosarcoma Protuberans with Fibrosarcomatous Areas:
New England Hand Society, Boston, MA
3. Giant Condyloma Acuminatum (Buschke-Loewenstein Tumor) of the Anorectal and Perianal Region: Analysis of 42 Cases
New England Cancer Society, Boston, MA

1994

4. The Role of Hepatic Re-Resection for Metastatic Colorectal Cancer
New England Cancer Society, Boston, MA

1995

5. Metastatic Squamous Cell Carcinoma (SCC) to the Neck from Unknown Primary.
American Radium Society
6. Biphasic Effect of Cisplatin and Taxol on B16F10 Melanoma Cells.
American Association for Cancer Research
7. Patient Selection for Hepatic Resection of Colorectal Metastases.
New England Surgical Society, Montreal, Canada
8. Repeat Hepatic Resection for Recurrent Colorectal Cancer
Society of Surgical Oncology

9. Purification of a Novel Human Antitumor Factor: Normal Human Globulin (NHG) from Normal Human Serum.
J. Murray Beardsley Surgeon-in-Chief Pro Tempore, Providence, RI

1996

10. Age, Mechanism of Injury, and Injury Severity Score as Predictors of Financial Outcome in Regional Pediatric Trauma Care: A New Outcome-Based Injury Prevention Strategy.
American College of Surgeons, San Francisco, CA

1997

11. Cost Analysis of Pediatric Trauma Care by Cost Centers and Mechanisms of Injury as a Basis for Injury Prevention and Clinical Guidelines.
Western Trauma Association, Snowbird, Utah
12. The Economic Burden of Preventable Pediatric Traumas to An Urban Level I Trauma Center.
Massachusetts American College of Surgeons Committee on Trauma, Boston, MA

1998

13. Delayed Hemothorax Following Blunt Thoracic Trauma. An Uncommon Entity with Significant Morbidity
Eastern Association for the Surgery of Trauma

1999

14. The Management of Breast Cancer.
General Surgery at the Millenium: Nursing Education Symposium, Boston, MA

2000

15. The Management of Thyroid Cancer.
Nursing Education Symposium III. Surgery for a Multidisciplinary Age, Boston, MA

2001

16. Abdominoperineal Resection as an Option for Patients with Stage IV Adenocarcinoma of the Rectum.
2nd Cancer Symposium of World Federation of Surgical Oncology Societies, Naples, Italy
17. Squamous Cell Carcinoma of the Lip: Nodal Stage Remains the Most Accurate Predictor of Outcome for Stage III/IV Disease.
American Head and Neck Society, Palm Desert, CA

2002

18. Predictive Factors Associated with Long Term Survival in Patients with Neuroendocrine Tumor of the Pancreas.
Society of Surgical Oncology, Denver, CO
19. Phase II Trial of Infusional 5-Fluorouracil, Mitomycin C, and External Beam Radiation Followed by Pancreatectomy for Patients with Locally Advanced Adenocarcinoma of the Pancreas. A Long-Term Follow-up.
American Society of Clinical Oncology,
20. Neuroendocrine Tumors of the Pancreas. The Roswell Park Experience.
Society of Black Academic Surgeons, Atlanta, GA
21. Parathyroid Carcinoma: A 30 year Review of the Western New York Experience.
American Academy of Otolaryngology Head & Neck Surgery, San Diego, CA
22. HsMCM2/BM28: A Potentially Better Proliferation Marker than Ki-67 for Squamous Cell Carcinoma of the Head and Neck.
American Society of Clinical Oncology,
23. Immunohistochemical Evaluation of Urinary Plasminogen Activator (uPA), its Receptor (uPAR), matrixmetalloproteinases-9 (MMP-9) and von Willebrand Factor (vWF) in Pancreatic Cancer.
American Association for Cancer Research, San Francisco, CA
24. Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Adenocarcinoma of the Pancreas: The Roswell Park Experience.
Society of Black Academic Surgeons, Atlanta, GA
25. Urinary Plasminogen Activator (uPA) is Expressed in Papillary Thyroid Carcinoma but Not in Benign Thyroid Tumor.
American Head and Neck Society, Boca Raton, FL

2003

26. High eIF4E Predicts Recurrence in Node-Negative Breast Cancer Patients.
American Society for Clinical Oncology, Chicago, IL
27. High eIF4E Predicts Cancer Recurrence in Node-positive Breast Carcinoma.
American Association for Cancer Research, Washington D.C.
28. Referral to American Cancer Society May Not Improve the Quality of Life for Patients with Breast Cancers.
Lynn Sage Cancer Symposium, Chicago, IL
29. Neoadjuvant Chemotherapy Attenuates the Overexpression of eIF4E in Patients with Breast Carcinomas.
Frontiers in Cancer Prevention Research, AACR, Phoenix, AZ
30. Radical Resection is Indicated For All T2 and T3 Gallbladder Cancers and Results in the Same Survival as Primarily Resected Gallbladder Cancers.
Society of Surgical Oncology, New York City, NY

2004

31. Impact of eIF4E Overexpression On Survival In Advanced Breast Cancer.
Joint Annual Meeting of the LA-Chapter, American College of Surgeons & Surgical Association of Louisiana, New Orleans, LA

32. Eukaryotic Initiation Factor 4E (eIF4E) is Overexpressed in Patients with Soft Tissue Neoplasms.
American Association for Cancer Research, Orlando, FL
33. Overexpression of eIF4E is Attenuated Following Neoadjuvant Chemotherapy for Patients with Breast Carcinomas.
Barlow Symposium, Shreveport, LA
34. eIF4E Overexpression Portend a Poorer Survival for Patients with Advanced Breast Cancer.
Barlow Symposium, Shreveport, LA
35. The Risk for malignancy in PET-Positive Thyroid Incidentalomas.
American Society of Clinical Oncology, New Orleans, LA
36. A Translational Restricted HSV-TK/GCV Gene Increases Disease-free and Overall Survival in a Minimal Residual Disease Rat Breast Cancer Model.
Association for Academic Surgery, Houston, TX
37. FDG-PET Imaging of Suspicious Breast Lesions Developing After Breast Conservation Therapy for Breast Cancer.
American Society of Clinical Oncology, New Orleans, LA
38. Therapeutic Efficacy of Translational Restricted Modified HSK-TK/GCV Gene Therapy Following Tumor Cytoreduction in a Syngeneic Rat Model for Breast Cancer.
Barlow Symposium, Shreveport, LA
39. Breast Conservation Therapy Can Be An Acceptable Alternative For Breast Cancer Patients With Collagen Vascular Disease.
Society of Surgical Oncology, NYC, NY
40. Positron Emission Tomography is a Useful Modality for the Detection of Metastasis in Symptomatic Patients with Stage II and III Breast Cancer.
American Society of Clinical Oncology, New Orleans, LA
41. Impact Of eIF4E Overexpression On Survival In Advanced Breast Cancer. Society of Surgical Oncology, NYC, NY
42. Thoracic Metastases from Breast Cancer: A 23-year Review of Patients. European Respiratory Society Glasgow 2004 Congress, Glasgow, Ireland

2005

43. Impact of Neoadjuvant Therapy on Stage III Breast Cancer Outcome. Southeastern Surgical Association 2005
44. Using an Ad-HSV-UTK Gene Construct to Exploit eIF4E Overexpression in Tumor Cells to Improve Outcome. Society of University Surgeons 2005, Nashville, TN
45. Eukaryotic Initiation Factor 4E (eIF4E) Expression in Malignant Versus Inflammatory Colon Tissue. Society of Surgical Oncology 2005, Atlanta, GA
46. Initiation Factor 4E (eIF4E) and Cancer Recurrence in Node-Positive Breast Carcinoma. American Surgical Association 2005; Palm Beach, FL
47. Effect of neoadjuvant chemotherapy on eIF4E expression in breast carcinoma. Society of Surgical Oncology 2005, Atlanta, GA
48. PET Scan and Stage II and III Breast Cancer.
Joint Meeting of the LA-Chapter, Amer Coll of Surgeons/Surg Assoc LA, New Orleans, LA

- 49. Role of Neoadjuvant Chemotherapy in Patients With Advanced Breast Cancer.
Joint Meeting of the LA-Chapter, Amer Coll of Surgeons/Surg Assoc LA, New Orleans, LA
- 50. Risk of Malignancy in PET Scan Detected Thyroid Incidentaloma
Joint Meeting of the LA-Chapter, Amer Coll of Surgeons/Surg Assoc LA, New Orleans, LA
- 51. Eukaryotic Initiation Factor 4E (eIF4E) Targeted Gene Therapy Increases Disease-Free and Overall Survival in a Minimal Residual Disease Rat Breast Cancer Model.
Joint Meeting of the LA-Chapter, Amer Coll of Surgeons/Surg Assoc LA, New Orleans, LA
- 52. Neoadjuvant Chemotherapy In Stage III Breast Cancer.
Southeastern Surgical Congress, New Orleans, LA
- 53. eIF4E Overexpression, Angiogenesis, and Breast Cancer Outcome
Annual Meeting of the Southern Surgical Association, Hot Spring, VA

2006

- 48. Apoptosis in a Malignant Cell Line Induced by a Novel Suicide Gene Therapy Exploiting Elevated Levels of Eukaryotic Initiation Factor 4E. Academic Surgical Congress 2006, San Diego, CA
Correlation of TLK1B in Elevation and Recurrence in Doxorubicin-treated Breast Cancer Patients with High eIF4E overexpression. Southern Surgical Association 2006, West Palm Beach, FL
- 49. Upregulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated breast cancer patients. Academic Surgical Congress 2006, San Diego, CA
- 50. Cost Analysis of Breast Conservation Therapy versus Simple Mastectomy with or without Reconstruction for Patients with Ductal Carcinoma In-Situ (DCIS). Society of Surgical Oncology 2006, San Diego, CA
- 54. eIF4E overexpression and Clinical Outcome in Node-negative Breast Cancer Patients – An Interim Analysis
Joint Meeting of the LA-Chapter, Amer Coll of Surgeons/Surg Assoc LA, New Orleans, LA
- 55. The Overexpression of eIF4E in Malignant Versus Inflammatory Colon Tissue.
Joint Meeting of the LA-Chapter, Amer Coll of Surgeons/Surg Assoc LA, New Orleans, LA

2007

- 56. High chemokine receptor CXCR4 in cancer specimens predicts recurrence in HER-2 negative breast cancer. Second Annual Academic Surgical Congress February 2007, AAS, Phoenix, AZ
- 57. A novel suicide gene therapy targeting the overexpression of eukaryotic initiation factor 4E improves survival in a rat model of peritoneal carcinomatosis. Second Annual Academic Surgical Congress February 2007, SUS, Phoenix, AZ
- 58. Risk for residual cancer after a margin-positive biopsy. 60th Annual Cancer Symposium. Society of Surgical Oncology 2007, Washington, DC.
- 59. Multi-dosing of a novel suicide gene therapy targeting the overexpression of eukaryotic initiation factor 4E improves outcome in a rat model of peritoneal carcinomatosis. 2nd International Symposium on Regional Cancer Therapies 2007, San Juan, Puerto Rico
- 61. A novel conditionally replicative adenovirus gene therapy targeting overexpression of chemokine receptor CXCR4 in a pancreatic cancer cell line. 7th American Hepato-Pancreato-Biliary Congress 2007, Las Vegas, Nevada

- 62. A novel suicide gene therapy regimen targeting the overexpression of eukaryotic initiation factor 4E in a pancreatic cancer cell line. 7th American Hepato-Pancreato-Biliary Congress 2007, Las Vegas, Nevada.
- 63. Long bone metastases in breast cancer: Experience of 47 patients. 4th Congress of the World Society for Breast Health, Tianjin, China, October 21, 2007

2008

- 64. Chemokine Receptor CXCR4 overexpression predicts recurrence for hormone-receptor positive, node-negative breast cancer patients. 3rd Annual Academic Surgical Congress 2008, Huntington Beach, CA
- 65. Translation initiation factor eIF4E targeted suicide gene therapy following cytoreductive surgery improves disease-free survival in a mouse soft tissue metastasis model for head and neck squamous cell carcinoma. 3rd Annual Academic Surgical Congress 2008, Huntington Beach, CA.
- 66. Hypoxia induces CXCR4 overexpression in pancreatic cancer cells. AACR 2008, San Diego, CA.
- 67. Cancerization of the lobules with pre-invasive or early invasive carcinoma of the breast: Management and outcome study. World Cancer Congress UICC 2008, Geneva, Switzerland.
- 68. Overexpression of chemokine receptor CXCR4 in cancer specimens predicts outcome in patients with triple-negative breast cancer. Annual meeting of the American Society of Clinical Oncology 2008, Chicago, IL.

2009

- 69. Eukaryotic initiation factor 4E (eIF4E) overexpression in triple-negative breast cancer and clinical outcome. 4th Annual Academic Surgical Congress, Fort Myers, FL February 3-6, 2009
- 70. Reduction in eIF4E level correlates with improved breast cancer outcome in patients treated with neoadjuvant chemotherapy. 4th Annual Academic Surgical Congress, Fort Myers, FL February 3-6, 2009
- 71. Testing an oncolytic adenovirus for cancer therapy using a novel ex vivo tissue slice model system. 4th Annual Academic Surgical Congress, Fort Myers, FL February 3-6, 2009
- 72. Race has no impact on breast cancer outcome: Results of 803 patients treated at a public hospital. Second AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Carefree, AZ February 3-6, 2009
- 73. Elevated Level of CXCR4 in Primary Tumors of HER-2 Negative Breast Cancers Portends a Poor Disease-Free Survival: A Validation Study. 62nd Annual Cancer Symposium of the Society of Surgical Oncology, March 5-8, 2009, Phoenix, AZ.
- 74. SIRT 1 and eIF4E in Colon Cancer Outcome. 62nd Annual Cancer Symposium of the Society of Surgical Oncology, March 5-8, 2009, Phoenix, AZ.
- 75. CXCR4 Chemokine Receptors and its Prognostic Significance in Breast Carcinoma. 2009 SWOG Spring Meeting, April 30-May 4, 2009, Chicago, IL.
- 76. Fundamentals of Clinical Surgery. Vietnam Education Foundation 2009 Meeting, June 22, 2009, Washington D.C.

77. SIRT 1 and eIF4E in Colorectal Cancer Outcome. The American Society of Colon and Rectal Surgeons Annual Scientific Meeting, Hollywood, FL May 2-6, 2009.
78. Concomitant eIF4E and TLK1B overexpression in doxorubicin-treated breast cancer. Surgical Forum, October 12, 2009, Chicago, IL.
79. A novel conditionally replicative adenovirus (Crad) increases infectivity efficiency and oncolytic activity in a human pancreatic adenocarcinoma cell line. 2009 Louisiana Gene Therapy Research Consortium Symposium October 14, 2009, New Orleans, LA.
80. Impact of Race/Ethnicity on Outcome for ER-Negative Breast Cancers: Experience of an Academic Center with a Charity Hospital. Southern Surgical Association, 121st Annual Meeting, Hot Springs, VA, December 6-9, 2009.
81. The Value of a Surgical Morbidity and Mortality Conference. Thai-Binh Medical University, Vietnam, December 15, 2009.
82. CXCR4 expression is not associated with HER-2 status or mTOR expression levels. ASCO 2009

2010

83. Hypoxia-Inducible Factor-1 α (HIF-1 α) Mediates Chemokine Receptor CXCR4 Expression under Hypoxic Condition in Human Pancreatic Cancer Line CFPAC-1. 5th Annual Academic Surgical Congress 2010, San Antonio, TX, February 3-5, 2010.
84. Race/Ethnicity Has No Impact on Outcome for Patients with Triple-Receptor Negative Breast Cancer. 5th Annual Academic Surgical Congress 2010, San Antonio, TX, February 3-5, 2010.
85. Testing a tropism-modified conditionally replicative adenovirus for breast cancer in a tissue slice model system. 5th Annual Academic Surgical Congress 2010, San Antonio, TX, February 3-5, 2010.
86. Persistently Elevated Chemokine Receptor CXCR4 in Primary Tumors Following Neoadjuvant Chemotherapy is a Novel Predictive Molecular Marker for Patients with Locally Advanced Breast Cancer. 5th Annual Academic Surgical Congress 2010, San Antonio, TX, February 3-5, 2010.
87. Breast Conservation Therapy is a Viable Option for Patients with Triple-Receptor Negative Breast Cancer. 5th Annual Academic Surgical Congress 2010, San Antonio, TX, February 3-5, 2010.
88. Fundamentals of Clinical Surgery. 7th Annual Meeting of Vietnam Education Foundation (VEF). January 2-4, 2010, Troy, New York.
89. Disparities in Breast Cancer: LSUHSC-S/FWCC Experience. John C. McDonald Surgical Society 2010 Annual Alumni Meeting: March 20, 2010, Eldorado Resort & Casino, Shreveport, LA.
90. Oncolytic activity of a novel conditionally replicative adenovirus (CRAD) against PANC-1 pancreatic adenocarcinoma cells. 9th World Congress of the International Hepato-Pancreato-Biliary Association. April 18-22, 2010, Buenos Aires, Argentina.
91. Multidisciplinary management of acute pancreatitis complications: experience in 104 patients. 9th World Congress of the International Hepato-Pancreato-Biliary Association. April 18-22, 2010, Buenos Aires, Argentina.
92. Major pancreatic surgery, a safe procedure. 9th World Congress of the International Hepato-Pancreato-Biliary Association. April 18-22, 2010, Buenos Aires, Argentina.

93. Updates on Developing Oncology Program at Hue University Hospital, Vietnam. International Cancer Corps Working Group. 2010 ASCO Annual Meeting. June 3-8, 2010, Chicago, IL.
94. ASCO Membership Recruitment and Retention. ASCO Leadership Development Program Presentation. 2010 ASCO Annual Meeting. June 3-8, 2010, Chicago, I.L.
95. What Does a Surgical Oncologist Do? Thai-Binh Medical University, Thai-Binh, Vietnam. June 28, 2010.
96. Multidisciplinary Approach to Breast Cancer Care. Vietnam Education Foundation. June 28, 2010.
97. Barrett's Esophagitis and its Progression to Cancer. 17th Annual Carroll W. Feist Scientific Symposium on Esophageal Carcinoma. July 23, 2010. LSU-Health Sciences Center-Shreveport, Shreveport, LA.
98. Management of Operable Breast Cancer. First Annual International Vietnam-American Surgical Symposium. October 3, 2010. Hanoi, Vietnam.
99. Current Perspectives on the Surgical Management of Breast Cancer. 2nd Annual University of Kansas Cancer Symposium. October 16, 2010. Kansas City, Kansas.
100. The Surgical Management of Early Breast Cancer. Hue University College of Medicine and Pharmacy. September 28, 2010. Hue, Vietnam.

2011

101. Sustained Chemokine Receptor CXCR4 in Primary Tumors Following Neoadjuvant Chemotherapy is a Novel Predictive Molecular Marker for Patients with Locally Advanced Breast Cancer. Louisiana Chapter of the American College of Surgeons Annual Meeting January 21-23 Annual Meeting, Shreveport, Louisiana.
102. Independent Prognostic Marker for Node Positive Breast Cancer Patients: Chemokine Receptor CXCR4. Louisiana Chapter of the American College of Surgeons Annual Meeting January 21-23 Annual Meeting, Shreveport, Louisiana.
103. Is Breast Conservation Therapy a Viable Option for Patients with Triple-Receptor Negative Breast Cancer? Louisiana Chapter of the American College of Surgeons Annual Meeting January 21-23 Annual Meeting, Shreveport, Louisiana.
104. Race/Ethnicity has no impact on outcome for patients with triple-receptor negative breast cancer. Louisiana Chapter of the American College of Surgeons Annual Meeting January 21-23 Annual Meeting, Shreveport, Louisiana.
105. Does early clinical exposure impact medical students' choices of primary care and surgical residencies? Louisiana Chapter of the American College of Surgeons Annual Meeting January 21-23 Annual Meeting, Shreveport, Louisiana.
106. Quality of resident research presentations: Impact of PowerPoint training versus prior oral presentation experience. Louisiana Chapter of the American College of Surgeons Annual Meeting January 21-23 Annual Meeting, Shreveport, Louisiana.
107. Impact of a program of early clinical exposure on medical students' residency choices of primary care and surgical fields. 6th Annual Academic Surgical Congress, February 1-3, 2011, Huntington Beach, California.
108. Prior presentation experience, not education on effective use of PowerPoint, predicts quality of resident research presentations. 6th Annual Academic Surgical Congress, February 1-3, 2011, Huntington Beach, California.

109. Is cost the reason for the lack of a sustaining “twinning” surgical program between the U.S. and a developing country? Experience with a university in Vietnam. 6th Annual Academic Surgical Congress, February 1-3, 2011, Huntington Beach, California.
110. Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer. 6th Annual Academic Surgical Congress, February 1-3, 2011, Huntington Beach, California.
111. CXCR4 tumor specific promoter restricts oncolysis to pancreatic cancer cell lines that overexpress CXCR4. 6th Annual Academic Surgical Congress, February 1-3, 2011, Huntington Beach, California.
112. A novel modified oncolytic adenovirus Ad5/3-CXCR4 exhibits potent antitumor effect and limited host toxicity against xenograft human pancreatic cancers on SCID mice. 6th Annual Academic Surgical Congress, February 1-3, 2011, Huntington Beach, California.
113. The Management of Locally Advanced Breast Cancer. Thai-Binh Medical University. May 27, 2011. Thai-Binh City, Vietnam.
114. Triple negative breast cancer (TNBC) with high eIF4E and TLK1B Co-expression predicts doxorubicin resistance. 97th Annual Clinical Congress of the American College of Surgeons, October 23-27, 2011, San Francisco, California.
115. Should a routine metastatic work-up be performed for all patients with N2/N3 breast cancer? Southern Surgical Association

2012

116. Does race/ethnicity, insurance status affect outcome in patients with gunshot wound to the abdomen? 7th Annual Meeting of the Academic Surgical Congress 2012, February 14-16, 2012, Las Vegas, NV.
117. Accuracy and impact of PET-CT in the diagnosis and management of pancreatic lesions. 7th Annual Meeting of the Academic Surgical Congress 2012, February 14-16, 2012, Las Vegas, NV.
118. Peripancreatic soft tissue involvement as a novel independent predictor of outcome for patients with resected pancreatic malignancy. 7th Annual Meeting of the Academic Surgical Congress 2012, February 14-16, 2012, Las Vegas, NV.
119. Diagnostic discordance of intraoperative frozen-section pathology at an academic medical center. 7th Annual Meeting of the Academic Surgical Congress 2012, February 14-16, 2012, Las Vegas, NV.
120. Management of Soft Tissue Sarcoma in a Rural Setting. Southeastern Surgical Congress, February 11-14, 2012, Birmingham, AL
121. A Matched Control Study of Survival in African Americans with Advanced Melanoma. Southeastern Surgical Congress, February 11-14, 2012, Birmingham, AL
122. Vascular resection and reconstruction for a replaced right hepatic artery can be avoided during a pancreaticoduodenectomy procedure. 2012 Americas Hepato-Pancreato-Biliary Association Annual meeting, March 7-11, 2012, Miami, FL
123. Vascular resection and reconstruction for a replaced right hepatic artery can be avoided during a pancreaticoduodenectomy procedure. 2012 International Hepato-Pancreato-Biliary Association Annual meeting, July 1-4, 2012, Paris, France.
124. The Role of CT, PET, PET/CT, and Tumor Marker CA19-9 for Monitoring Recurrence of Pancreatic Adenocarcinoma. 2012 International Hepato-Pancreato-Biliary Association Annual meeting, July 1-4, 2012, Paris, France.

125. The Role of Positron Emission Tomography in the Diagnosis and Staging of Pancreatic Lesion. 2012 International Hepato-Pancreato-Biliary Association Annual meeting, July 1-4, 2012, Paris, France.
126. A strategy and guidelines proposal for effective percutaneous drainage of pancreatic collections: Results on 121 patients. 2012 International Hepato-Pancreato-Biliary Association Annual meeting, July 1-4, 2012, Paris, France.
127. Curative Resection of the Pancreatic Cancer with Major Venous Resection/Repair is a Safe Procedure. 2012 International Hepato-Pancreato-Biliary Association Annual meeting, July 1-4, 2012, Paris, France.

2013

128. Is chronic kidney disease an independent risk factor for mortality in breast cancer? 8th Annual Academic Surgical Congress, February 5-7, 2013, New Orleans, LA.
129. Does obesity have an impact on outcomes in triple-negative breast cancer? 8th Annual Academic Surgical Congress, February 5-7, 2013, New Orleans, LA.
130. Surgical resident learning styles: faculty and resident accuracy at identification of preferences and impact on ABSITE Scores. 8th Annual Academic Surgical Congress, February 5-7, 2013, New Orleans, LA.
131. Laparoscopic vs open liver resection for benign and malignant solid liver tumors: a case matched study. SAGES 2013 Annual Meeting. April 17-30, 2013, Baltimore Convention Center.
132. Effects of January vacations and prior night call status on resident ABSITE performance. Association of Program Directors in Surgery 2013, Orlando, Florida.
133. Laparoscopic vs open liver resection for benign and malignant solid liver tumors: a case matched study. 2013 LA-ACS/SAL Annual Meeting, New Orleans, LA
134. Is surveillance mammogram useful in detecting occult recurrences in women previously treated for primary breast cancer? 2013 LA-ACS/SAL Annual Meeting, New Orleans, LA
135. Current Perspectives on Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. 113th Annual Congress of Japan Surgical Society, Fukuoka, Japan, April 11, 2013.
136. Should all patients receive neoadjuvant therapy for pancreatic cancer? Jikei University, Tokyo, Japan, April 8, 2013.
137. Current Update on Pancreatic Cancer. 3rd Workshop for HPBA. Managua, Nicaragua November 15, 2013.
138. Overexpression of eIF4E increases risk for systemic dissemination in node-positive breast cancer patients. 125th Annual Meeting of the Southern Surgical Association. December 1-4, 2013, Homestead, Hot Springs, Virginia

2014

139. Outreach to Nicaragua: AHPBA Humanitarian Medical Outreach Teams: Supporting Local Chapters with Capacity Building. AHPBA Annual Meeting, Miami Beach, FL, Feb 19-23, 2014.

140. A novel oncolytic adenovirus targeting c-met receptor increases infectivity efficiency and oncolytic activity in human pancreatic adenocarcinoma cell lines. AHPBA Annual Meeting, Miami Beach, FL, Feb 19-23, 2014.
141. The impact of surgical resident learning style preferences on ABSITE Scores. ASE 2014 Annual Meeting, April 10-12, 2014, Chicago, IL
142. Accuracy of pre-operation multi-detector computed tomography in detecting vascular, nodal, peripancreatic soft tissue involvement and prediction of outcome in patients with pancreatic adenocarcinoma. Annual meeting of the LA-ACS Chapter, New Orleans, Louisiana, January 17, 2015.
143. Postmastectomy radiation (PMRT) for N2/N3 breast cancer: Factors associated with low compliance rate. Southern Surgical Association, The Breakers, Palm Beach, Florida, November 30-December 3, 2014
144. Management of Traumatic Pancreatic Injury. Duhok, Kurdistan 2014

2016

146. Can radiation therapy adequately address positive surgical margins in elderly women (≥ 70 years) with stage I, ER+ breast cancer? LA-ACS Annual Meeting, January 15, 2016
147. Inadequate lymph nodes retrieved, lack of receipt of adjuvant chemotherapy, and socioeconomic factors contribute to the poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2N1, T1N2A) colon cancer. LA-ACS Annual Meeting, January 15, 2016
148. Effect of facility type on outcome following pancreatectomy for pancreatic adenocarcinoma: analysis of the national cancer data base. LA-ACS Annual Meeting, January 15, 2016
149. Minimal Impact of Cooperative Trial and Sociodemographic Variation of Radiation Therapy Usage in Elderly Patients (≥ 70 years) with Stage I, ER+/PR+ Breast Cancer: Analysis of the National Cancer Data Base. LA-ACS Annual Meeting, January 15, 2016
150. Effect of facility type on outcome following pancreatectomy for pancreatic adenocarcinoma: analysis of the national cancer data base. 12th World Congress of the IHPBA and AHPBA, April 20-23, 2016. Sao Paulo, Brazil
151. Accuracy of pre-operation multi-detector computed tomography (MDCT) in detecting vascular, nodal, peripancreatic soft tissue (PST) involvement and prediction of outcome in patients with pancreatic adenocarcinoma. 12th World Congress of the IHPBA and AHPBA, April 20-23, 2016. Sao Paulo, Brazil
152. Positive margins contribute to the survival paradox between stage 2B/C and stage 3A colon cancer. 11th Annual Academic Surgical Congress, February 2-4, 2016. Jacksonville, Florida
153. Pre-treatment evaluation of LVEF for breast cancer patients receiving anthracyclines: Is it necessary. ASCO 2016
154. Can radiation therapy adequately address positive surgical margins in elderly women (≥ 70 years) with Stage I, ER+ Breast Cancer. ASCO 2016

2017

155. Lancet Commission on Global Surgery. TexMed May 5-6, 2017. Houston
156. Lancet Commission on Global Surgery. 8th Annual Joint Americas HepatoPancreato-Biliary Association, Operation Hope, World Surgical Foundation & the American Kurdish Medical Group Symposium, Duhok-Kurdistan, Iraq, May 25, 2017

157. Role of Local Excision for benign and malignant ampullary and peri-ampullary lesions. 2107 Annual Meeting of Louisiana Chapter of the American College of Surgeons, June 2-4, 2017, New Orleans, Louisiana
158. Perioperative complications differ between patients who underwent neoadjuvant chemoradiation therapy versus up-front pancreaticoduodenectomy. 2107 Annual Meeting of Louisiana Chapter of the American College of Surgeons, June 2-4, 2017, New Orleans, Louisiana
159. Major pancreas resection for adenocarcinoma in the elderly patients: does age impact outcome? 2107 Annual Meeting of Louisiana Chapter of the American College of Surgeons, June 2-4, 2017, New Orleans, Louisiana
160. Resident duty hours and American Board of Surgery in-Training Examination Performance. 2107 Annual Meeting of Louisiana Chapter of the American College of Surgeons, June 2-4, 2017, New Orleans, Louisiana
161. Pilot study of Savi Scout to localize non-palpable breast lesions significantly reduces re-excision rate compared to wire localization. 2107 Annual Meeting of Louisiana Chapter of the American College of Surgeons, June 2-4, 2017, New Orleans, Louisiana
162. Pediatric pedestrians and bicyclists versus motor vehicle accidents: comparison of injury patterns by mechanism and influence of socioeconomic status. 2107 Annual Meeting of Louisiana Chapter of the American College of Surgeons, June 2-4, 2017, New Orleans, Louisiana
163. Discussant at the Southern Surgical Association 129th Annual Meeting, Hot Springs, VA, December 2017. JACS 2018;226:538-9.

2018

164. The Mortality for Surgical Repair is Lower than Ligation in Patients with Portal Vein Injury. 13th Annual Academic Surgical Congress, January 30 - February 1, 2018 in Jacksonville, FL.
165. Ligation and Repair are Associated with Similar Outcomes in Superior Mesenteric Vein Injury. 13th Annual Academic Surgical Congress, January 30 - February 1, 2018 in Jacksonville, FL.
166. Innovative Teaching Strategies for Surgery Resident Education Sessions. 13th Annual Academic Surgical Congress, January 30 - February 1, 2018 in Jacksonville, FL.
167. Is Integer-Based Risk Score to Predict in-hospital Mortality Following Pancreatectomy Reliable? 2018 AHPBA Annual Meeting
168. Management of Breast Cancer in Pregnant Women. 9th Annual Joint Americas Hepato Pancreato-Biliary Association, Operation Hope, World Surgical Foundation & the American Kurdish Medical Group Symposium, Duhok-Kurdistan, Iraq, August 30, 2018.

2019

169. The five-point modified frailty index (MFI-5) predicts surgical outcomes in pancreatic ductal adenocarcinoma patients undergoing pancreaticoduodenectomy. 2019 AHPBA Annual meeting at Loews Miami Beach Hotel, Miami, March 20-24, 2019.

2020

- 170 Operable breast cancer mortality in rural Louisiana: Results of the Louisiana Cancer Consortium. 15th Annual Academic Surgical Congress, February 4-6, 2020, Orlando, Florida.
- 171 Medical capacity building in war-torn nations: Kurdistan, Iraq as a model. 15th Annual Academic Surgical Congress, February 4-6, 2020, Orlando, Florida.
- 172 Higher breast cancer mortality in community center. 15th Annual Academic Surgical Congress, February 4-6, 2020, Orlando, Florida.
- 173 Treatment at high-volume academic research program mitigates racial/ethnic disparities in pancreatic adenocarcinoma. Annual Meeting of the Louisiana Chapter of the American College of Surgeons. New Orleans, Louisiana, January 17-19, 2020.
- 174 Breast cancer mortality for elderly women with early breast cancer is highest at community cancer center compared to comprehensive community cancer program and academic research program. Annual Meeting of the Louisiana Chapter of the American College of Surgeons. New Orleans, Louisiana, January 17-19, 2020.
- 175 Medical capacity building in war-torn nations: Kurdistan, Iraq as a model. Annual Meeting of the Louisiana Chapter of the American College of Surgeons. New Orleans, Louisiana, January 17-19, 2020.
- 176 Different approaches to management of common duct stone (CBDS) in patients who had roux-en-Y gastric bypass (RYGB). Annual Meeting of the Louisiana Chapter of the American College of Surgeons. New Orleans, Louisiana, January 17-19, 2020.
- 177 Rural residence does not predict outcome for resected pancreatic adenocarcinoma. Annual Meeting of the Louisiana Chapter of the American College of Surgeons. New Orleans, Louisiana, January 17-19, 2020.
- 178 Treatment at high-volume academic research program mitigates racial/ethnic disparities in pancreatic adenocarcinoma. AHPBA 2020 Annual Meeting, March 5-8, Loews Miami Beach Hotel, Miami Beach, FL 2020.
- 179 10-year survival after breast-conserving surgery is better than mastectomy for Louisiana women with early breast cancer: A population-based study. Virtual Southern Surgical Association 2020.

2021

- 180 Lower 10-year survival for mastectomy than breast conserving therapy among early-stage breast cancer patients. Presented at the North American Association of Central Cancer Registries Summer Forum, June 15-17, 2021.

181 Breast-conserving surgery plus radiation yielded better outcomes than mastectomy for all subtypes of early-stage breast cancer. Analysis of over 200,000 women. Southern Surgical Association 2021.

2022

182 Current Perspectives on Management of Esophageal Cancer. Grand Rounds to UC Merced, February 8, 2022.

183 The Tale of Two Hospitals. National Medical Association Surgical Section 2022 Annual Meeting. Excellence in Surgical Leadership. July 30, 2022 Morehouse College, Atlanta, GA.

184 Impact of Medicaid Expansion on Breast Cancer Diagnosis and Treatment in Southern States. 134th Annual Meeting of the Southern Surgical Association. Dec 4-7, 2022. The Breakers Resort, Palm Beach, FL

185 Is Adjuvant Chemotherapy Necessary for Stage I Appendiceal Adenocarcinoma. 130th Western Surgical Association 2022 Annual Meeting. Nov 5-8, 2022, The Ritz-Carlton Bacara, Santa Barbara, CA.

186. Is Adjuvant Chemotherapy Necessary for Stage IIB/IIC Appendiceal Adenocarcinoma. 130th Western Surgical Association 2022 Annual Meeting. Nov 5-8, 2022, The Ritz-Carlton Bacara, Santa Barbara, CA.

187. Do ACOSOG Z0011 Criteria Apply to Patients with ER-Negative Breast Cancer? 130th Western Surgical Association 2022 Annual Meeting. Nov 5-8, 2022, The Ritz-Carlton Bacara, Santa Barbara, CA.

188. A Modified Textbook Outcome (mTO) Results in Superior Outcome for Patients with Stage III Colon Cancer. 130th Western Surgical Association 2022 Annual Meeting. Nov 5-8, 2022, The Ritz-Carlton Bacara, Santa Barbara, CA.

189. Impact of Medicaid Expansion on Breast Cancer Diagnosis and Treatment in Southern States. 134th Annual Meeting of the Southern Surgical Association. December 4-7, 2022. The Breakers, Palm Beach, FL.

190. Pancreaticoduodenectomy for Distal Cholangiocarcinoma. 3rd PAHPBS International Symposium “HPB Standards of Care and Beyond”. December 1-2, 2022. ACE Hotel and Suites, Pasig City, Philippines.

2023

191. Survival Paradox Between Stage IIB/C and Stage IIIA Colon Cancer. Is It Time to Revise the American Joint Committee on Cancer TNM System? 2023 SAGES Annual Meeting. March 29-April 1, 2023, Montreal Convention Centre, Montreal, Quebec, Canada.
192. Rural versus urban commuting patients with Stage III colon cancer: is there a difference in treatment and outcome? 2023 SAGES Annual Meeting. March 29-April 1, 2023, Montreal Convention Centre, Montreal, Quebec, Canada.
193. Survival Paradox Between Stage IIB/C and Stage IIIA Colon Cancer. Is It Time to Revise the American Joint Committee on Cancer TNM System? Annual FCACS Conference, June 2-3, 2023. Orlando, FL.
194. Rural versus urban commuting patients with Stage III colon cancer: is there a difference in treatment and outcome? Annual FCACS Conference, June 2-3, 2023. Orlando, FL.
195. Adherence Rate to ACOSOG Z0011 Based on Breast Cancer Subtypes. 2023 Annual Meeting of the Southern Surgical Association. December 2023. The Breakers, FL
196. Early Cholecystectomy in Sickle Cell Patients with Gallstone Disease is Associated with Better Outcomes. 2023 Annual Meeting of the Southern Surgical Association. December 2023. The Breakers, FL
197. Medicaid expansion increases access for rural and impoverished patients with pancreatic cancer in southern states. Surgical Forum, Annual Clinical Congress of the American College of Surgeons, October 22-25, 2023, Boston, MA.

MEDIA PRESENTATIONS:

1. “Colorectal Cancer: Screening, Treatment and Advances” KDAQ (National Public Radio Affiliate), Shreveport, LA, February, 2006.
2. Current Perspectives on Management of Colorectal Cancer. Louisiana Comprehensive Cancer Control Program. October 19, 2007.
3. Race/ethnicity has no effect on outcome for breast cancer patients treated at an academic center with a public hospital. Lead article in LSU System Media Sweep 2009 and selected by The BreastCancer.Net News.
4. Race Does Not Affect Breast Cancer Outcome, Says “Pivotal” Study. http://www.medscape.com/viewarticle/709542_print 2009 Medscape Medical News.
5. Study indicates race may not be independent predictor of overall breast cancer survival. ASCO Cancer in the News, September 28, 2009. DailyCancerNews@asco.custombriefings.com.
6. Establishing a Breast Cancer Patient Navigator Program: The first of its kind at LSUHSC-Shreveport, November 2, 2009.
7. The Role of a Breast Cancer Patient Navigator. Community Renewal International. Shreveport, Louisiana, November 13, 2009.

8. Equal treatment, equal outcomes in aggressive breast cancer: \$10 million “down the drain?” http://www.medscape.com/viewarticle/722544_print 2010 Medscape Medical News.
9. Surgeon grows into a leader in Louisiana, ASCO, and Beyond. <http://www.medscape.com/viewarticle/727838>. 2010 Medscape Medical News.
10. Translational Research at the Feist-Weiller Cancer Center. KWKH, Shreveport, LA, July 2011.
11. “What does a surgical oncologist do?” Barksdale Air Force Base, Shreveport, LA 2010
12. “Linsanity” in Surgical Oncology? Asian American Bias Under Scrutiny. <http://www.medscape.com/viewarticle/759734>.
13. “Metastatic work-up revisited for N2/N3 Breast Cancer”. ACS Surgery News 2012;8:18
14. “Management of Breast Cancer”. Breast Cancer Awareness Month. Shreveport, LA 10/11/2012.
15. HVO/ICC Vietnam: Volunteers discuss personal experiences, national need. ASCO Daily News June 4, 2012.
16. “One-Third of Mastectomy Patients with Locally Advanced Breast Cancer Do Not Receive Postoperative Radiation Therapy as Recommended by Experts”. ACS Press Releases.
17. “Study: Only two thirds of N2/N3 breast cancer patients receive PMRT” ASCO Communications.
18. “Can Axillary Ultrasound Aid a Tricky Breast Cancer Decision?” Commentator for Medscape
19. What is Cancer? Presentation at Abounding Grace. November 21, 2016. Shreveport, LA
20. Speaker for the annual Shreveport Mayor’s Women Commission. February 2016. Shreveport, LA
21. What is SAVI Scout? Speaker for the Peri-Operative Seminar for Nurses. February 2016. Shreveport, LA
22. My-Lai Massacre. Speaker for Caddo Magnet High School History Class. April 2018.

MAJOR AREAS OF RESEARCH INTEREST

- (1) Role of CXCR4 chemokine receptor as a potential prognostic factor in HER-2 negative breast cancers
- (2) Utilizing novel oncolytic adenoviruses based on the overexpression of eIF4E and CXCR4 for the treatment of breast and pancreatic cancer
- (3) Cancer Disparities and public policies
- (4) Medical/Surgical Missions in Developing Countries